 | Harry Roger Büller |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Also Ranks for: Vte Patients | venous thromboembolism | prophylaxis lmwh | 3 months | practice guidelines |
KOL Index score: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Also Ranks for: Atrial Fibrillation | bled bleeding | hemorr2hages atria | intracranial hemorrhage | topic risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Also Ranks for: Antithrombotic Therapy | grade 1a | venous thromboembolic disease | vka lmwh | inr range |
KOL Index score: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Also Ranks for: Venous Thromboembolism | bleeding complications | patients malignancy | retrospective analysis | international normalized |
KOL Index score: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Also Ranks for: Venous Thromboembolism | patients cancer | hazard ratio | clinically relevant bleeding | factor inhibitors |
KOL Index score: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Also Ranks for: Warfarin Patients | hazard ratio | venous thromboembolism | pulmonary embolism | primary efficacy outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Also Ranks for: Willebrand Factor | venous thromboembolism | vte cancer | vwf adamts13 | khorana score |
KOL Index score: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Also Ranks for: Oral Rivaroxaban | venous thromboembolism | vitamin antagonist | continued treatment | hazard ratio |
KOL Index score: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Also Ranks for: Hip Replacement | dabigatran enoxaparin | venous thromboembolism | etexilate versus | primary efficacy outcome |
KOL Index score: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Also Ranks for: Pulmonary Embolism | computed tomography | dimer testing | patients suspected | 3 months |
KOL Index score: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Also Ranks for: Total Hip | dabigatran etexilate | thromboembolic events | knee replacement | vte patients |
KOL Index score: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Also Ranks for: Subcutaneous Enoxaparin | oral dabigatran | total knee replacement | venous thromboembolism | prevention vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Also Ranks for: Unfractionated Heparin | pulmonary embolism | initial treatment | subcutaneous fondaparinux | intravenous injections |
KOL Index score: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Also Ranks for: Anticoagulant Treatment | recurrent vte | unprovoked venous | 10 years | 95 confidence interval |
Harry Roger Büller: Influence Statistics
| Concept | World rank |
|---|---|
| strategy abdominal pelvic | #1 |
| segmental subsegmental | #1 |
| clinically suspected dvt | #1 |
| evaluable patients apixaban | #1 |
| rfviia fondaparinux | #1 |
| ufh grade | #1 |
| dvt 56 | #1 |
| doses 75 microg | #1 |
| thromboembolism relatives | #1 |
| outcome clinically | #1 |
| edoxabantreated | #1 |
| bleeding clinically | #1 |
| vte risk coc | #1 |
| presentation category | #1 |
| coagulation fibrinolytic proteins | #1 |
| relative risks carriers | #1 |
| pyridines recurrence | #1 |
| xainhibitors | #1 |
| lmwh plasma levels | #1 |
| reduceddose noacs | #1 |
| patients treatment duration | #1 |
| tb402 12 kg1 | #1 |
| venous thrombosis pregnancy | #1 |
| ddimer levels cdr | #1 |
| severe presentation patients | #1 |
| fetal loss carriers | #1 |
| fviii homocysteine | #1 |
| ldfr symptomatic legs | #1 |
| efficiency subgroups | #1 |
| rnapc2 groups | #1 |
| association protein levels | #1 |
| previous surveys netherlands | #1 |
| laalleles platelets | #1 |
| matisse clinical trials | #1 |
| 95 intracranial | #1 |
| plateletactivating antibodies risk | #1 |
| heparin initial treatment | #1 |
| intrinsic coagulation vivo | #1 |
| treatment venous | #1 |
| doacs initial heparin | #1 |
| lowmolecularweight heparin category | #1 |
| submassive elevated ctni | #1 |
| current comprehensions | #1 |
| anticoagulants probability | #1 |
| pvo qscan | #1 |
| lmwh rtap | #1 |
| intensity vkas doacs | #1 |
| vte procoagulant activity | #1 |
| uesvt uedvt | #1 |
| treated vka | #1 |
| strategies abdominal pelvic | #1 |
| plasma concentration fviii | #1 |
| timeperiod | #1 |
| pulmonary angiography strategies | #1 |
| withheld | #1 |
| pulmonary embolism carriers | #1 |
| diagnosis deepvein thrombosis | #1 |
| rnapc2 united states | #1 |
| thrombosis vte | #1 |
| coagulation factors markers | #1 |
| proximal extent ipe | #1 |
| recurrent dvt dvt | #1 |
| cancer patients uedvt | #1 |
| fxiaso enoxaparin | #1 |
| fondaparinux rfviia injection | #1 |
| dvt impedance plethysmography | #1 |
| cdrs patients | #1 |
| patients tests prevalence | #1 |
| subcutaneous length life | #1 |
| ddimer test patients | #1 |
| total vte patients | #1 |
| frequency venous thromboembolism | #1 |
| hokusaivte study | #1 |
| ecq ankle brachial | #1 |
| avws prevalence | #1 |
| therapeutic doses lmwh | #1 |
| efficacy vte | #1 |
| scores occult cancer | #1 |
| patients wells rule | #1 |
| smoking graft patency | #1 |
| extended treatment edoxaban | #1 |
| guidelines abi | #1 |
| progression vte | #1 |
| gastrointestinal cancer edoxaban | #1 |
| normal ddimer result | #1 |
| synthetic selective factor | #1 |
| hokusai‐vte trial | #1 |
| individualized duration | #1 |
| anticoagulant treatment patients | #1 |
| preferred oral anticoagulant | #1 |
| lmwh venous thrombosis | #1 |
| vka recipients | #1 |
| ml1 ctpa | #1 |
| predefined outcomes | #1 |
| qscan | #1 |
| strategies diagnostic management | #1 |
| lmwhmediated | #1 |
| standardintensity vkas | #1 |
| 3633 patients edoxaban | #1 |
| elevated levels fviii | #1 |
| milliliter enoxaparin | #1 |
| treatment idraparinux | #1 |
| pulmonary angiography study | #1 |
| normal ddimer concentration | #1 |
| amplify trial | #1 |
| increasing levels ft4 | #1 |
| animal female heparin | #1 |
| successful attenuation | #1 |
| edoxaban east asian | #1 |
| patients unexplained dvt | #1 |
| ft4 level patients | #1 |
| cip diagnostic management | #1 |
| standard treatment idraparinux | #1 |
| age recurrent vte | #1 |
| treat thrombosis | #1 |
| 65±9years | #1 |
| d‐dimer test | #1 |
| predefined outcomes vte | #1 |
| venous thrombosis mutations | #1 |
| nadroparin therapeutic dose | #1 |
| probabilityscan | #1 |
| recurrent vte doacs | #1 |
| submassive incidence | #1 |
| daily dalteparin treatment | #1 |
| ccus 4 | #1 |
| preference doacs | #1 |
| topic thrombophlebitis | #1 |
| ddimer test | #1 |
| casedescription | #1 |
| extra hospital visits | #1 |
| factor viii relatives | #1 |
| heparin survival | #1 |
| individuals air travel | #1 |
| safety clinical utility | #1 |
| major bleeds vka | #1 |
| dvt symptomatic | #1 |
| strategies ultrasonography | #1 |
| baseline pvo | #1 |
| patients laalleles | #1 |
| protein resistance control | #1 |
| simplified rule proportion | #1 |
| timerequirement | #1 |
| patients ivte | #1 |
| single dose tb402 | #1 |
| lmwh edoxaban | #1 |
| reduceddose noacs warfarin | #1 |
| venography feasibility | #1 |
| 95 3633 patients | #1 |
| anticoagulants chemotherapy | #1 |
| patients clinical probability | #1 |
| carriers recurrence | #1 |
| edoxaban warfarin groups | #1 |
| clinical uedvt | #1 |
| excluded pulmonary | #1 |
| incidental symptomatic vte | #1 |
| original wells | #1 |
| venous thrombosis recurrence | #1 |
| inr range ttr | #1 |
| factual hemorrhage heparin | #1 |
| rivaroxaban dvt treatment | #1 |
| matisse trials | #1 |
| uedvt recurrent vte | #1 |
| prediction models recurrence | #1 |
| mutation relatives | #1 |
| method factor | #1 |
| thrice daily gentamicin | #1 |
| studies 3 months | #1 |
| initial treatment patients | #1 |
| specificity pulmonary embolism | #1 |
| symptomatic recurrent | #1 |
| acquired atiii deficiency | #1 |
| administration lmwh | #1 |
| noacs prevention | #1 |
| incidence ctni | #1 |
| wells rule primary | #1 |
| isolated deficiencies proteins | #1 |
| cdr dimer | #1 |
| crptest | #1 |
| einsteinextension | #1 |
| 378 patients edoxaban | #1 |
| noncarriers annual incidence | #1 |
| months standard therapy | #1 |
| smoking patency | #1 |
| extensive screening cancer | #1 |
| inr studies | #1 |
| scores riete score | #1 |
| vte addition | #1 |
| cus strategies | #1 |
| chromogenic endotoxin | #1 |
| 25mg apixaban | #1 |
| oral edoxaban dose | #1 |
| guideline adherence justification | #1 |
| puerperium diagnostic suspicion | #1 |
| quantitative ddimer tests | #1 |
| edoxaban dalteparin | #1 |
| absolute annual incidences | #1 |
| limited screening 95 | #1 |
| clinical presentation category | #1 |
| intestinal microbiota coagulation | #1 |
| rhir lmwh | #1 |
| ventricular dysfunction edoxaban | #1 |
| relatives antithrombin | #1 |
| 3633 patients edoxabantreated | #1 |
| double heterozygous carriers | #1 |
| cdr physicians | #1 |
| apixaban conventional therapy | #1 |
| patients khorana | #1 |
| coagulationinhibiting | #1 |
| org heparin | #1 |
| fviii normal levels | #1 |
| lmwh replacement | #1 |
| axa activity 5 | #1 |
| ventilation lung scanning | #1 |
| tests prevalence abi | #1 |
| international thrombosis experts | #1 |
| initial heparin edoxaban | #1 |
| included patients study | #1 |
| venous thromboembolism idraparinux | #1 |
| influenza case patients | #1 |
| wells clinical | #1 |
| protein levels mortality | #1 |
| gentamicin patients netilmicin | #1 |
| qscan 3 weeks | #1 |
| calf dvt ultrasound | #1 |
| doacs cirrhosis patients | #1 |
| orthopedic thromboprophylaxis | #1 |
| leg veins patients | #1 |
| relatives elevated levels | #1 |
| patients reduceddose noacs | #1 |
| venous thrombosis hyperglycemia | #1 |
| xageneration | #1 |
| ultrasonography dvt | #1 |
| embolism suspected | #1 |
| 69 conclusions | #1 |
| fviii venous thromboembolism | #1 |
| clinical probability patients | #1 |
| age∗10μg | #1 |
| messages justification | #1 |
| threemonth incidence | #1 |
| pregnancyrelated complications relatives | #1 |
| intracranial clinical presentation | #1 |
| crt cvc | #1 |
| carriers pulmonary embolism | #1 |
| acenocoumarol heparin | #1 |
| —brachial | #1 |
| scan pulmonary embolism | #1 |
| ultrasonography diagnostic | #1 |
| idraparinux recurrent thromboembolism | #1 |
| combination cdrs | #1 |
| hokusai‐vte cancer study | #1 |
| superficial thrombophlebitis incidence | #1 |
| uesvt | #1 |
| nadroparin patients | #1 |
| vivo coagulation factor | #1 |
| netherlands vka | #1 |
| residual thrombotic mass | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| annual incidence patients | #1 |
| recurrent thrombosis pts | #1 |
| prolactin venous thrombosis | #1 |
| graft patency patency | #1 |
| leg ultrasonography patients | #1 |
| compression ultrasound dvt | #1 |
| venous thrombus growth | #1 |
| vte airline pilots | #1 |
| mutation arg506 | #1 |
| pulmonary embolism idraparinux | #1 |
| elevated biomarkers hospital | #1 |
| chest perfusion scan | #1 |
| vte study | #1 |
| level loss patency | #1 |
| clinical decision rule | #1 |
| rule dimer | #1 |
| doacs anatomical extent | #1 |
| prothrombin 20210a mutation | #1 |
| nadroparin aspirin | #1 |
| atherosclerosis hemophilia patients | #1 |
| patients compression ultrasonography | #1 |
| neoplasms heparin | #1 |
| s1p1activation | #1 |
| thrombophilia late loss | #1 |
| weight heparinoid | #1 |
| prophylaxis idraparinux | #1 |
| studies ttr | #1 |
| netherlands lmwh | #1 |
| patency smokers | #1 |
| idraparinux 25 | #1 |
| heparins vitamin antagonists | #1 |
| prospective management study | #1 |
| compression ultrasonography presentation | #1 |
| consensus strategy strategy | #1 |
| combination nonhigh cdr | #1 |
| initial heparin patients | #1 |
| uedvt clinical | #1 |
| scenarioanalysis | #1 |
| respondents 60 | #1 |
| dvt 69 | #1 |
| vte trial | #1 |
| outcome recurrent | #1 |
| cancer cdr | #1 |
| sspe proximal | #1 |
| dvt costs | #1 |
| selective beta‐blocker treatment | #1 |
| efficacy conventional treatment | #1 |
| mdct expert radiologist | #1 |
| ddimer test result | #1 |
| evaluable patients 95 | #1 |
| hokusai vte cancer | #1 |
| dimer clinical | #1 |
| iii plg | #1 |
| pulmonary embolism role | #1 |
| hellp syndrome mutations | #1 |
| protein mortality | #1 |
| ankle brachial prevalence | #1 |
| dimer test | #1 |
| controlled trials thrombophilia | #1 |
| 023 relatives | #1 |
| departments orthopedic surgery | #1 |
| malignancy achieved inr | #1 |
| embolism radionuclide | #1 |
| patients artificial graft | #1 |
| efficacy outcome | #1 |
| uesvt recurrent vte | #1 |
| avidin placebo | #1 |
| wellscdrscore | #1 |
| tinaquant assay comparison | #1 |
| 20210a mutation | #1 |
| beta thromboglobulin org | #1 |
| enoxaparin initial treatment | #1 |
| analysis hokusai | #1 |
| rtap lmwh | #1 |
| probability categories | #1 |
| idraparinux months | #1 |
| patients acute recurrent | #1 |
| ultrasonography leg veins | #1 |
| edoxaban cancer patients | #1 |
| time recombinant | #1 |
| idraparinux vte | #1 |
| fxainhibitors | #1 |
| aged nadroparin | #1 |
| apc resistance factor | #1 |
| enoxaparin heparin treatment | #1 |
| diagnostic management patients | #1 |
| endotoxemia tests | #1 |
| tb402 enoxaparin | #1 |
| anticoagulants double | #1 |
| relatives normal fviii | #1 |
| anticoagulant fondaparinux | #1 |
| d‐dimer level | #1 |
| antithrombotic prescriptions adherence | #1 |
| rivaroxaban standard therapy | #1 |
| oral administration bsf | #1 |
| vitamin anticoagulants | #1 |
| 95ci tb402 | #1 |
| patients advanced malignancy | #1 |
| fviii women | #1 |
| levels procoagulant factors | #1 |
| 50 years combination | #1 |
| elevated fviii | #1 |
| pvo ctscan | #1 |
| ctscanreading | #1 |
| dose rnapc2 | #1 |
| quantitative dimer | #1 |
| replacement vka | #1 |
| patients idraparinux | #1 |
| fibrinolysis levels | #1 |
| fetal loss stillbirth | #1 |
| tests pulmonary embolism | #1 |
| 5 years lmwh | #1 |
| adjunct thrombolysis | #1 |
| heparins cancer spread | #1 |
| crp test patients | #1 |
| clinically suspected cancer | #1 |
| diagnostic strategies patients | #1 |
| elevated cardiac troponins | #1 |
| dose response apixaban | #1 |
| venography tests | #1 |
| clinical probability risk | #1 |
| hokusaivte trial | #1 |
| einstein dvt patients | #1 |
| 12 months edoxaban | #1 |
| ambulatory computers | #1 |
| non‐invasive diagnostic work‐up | #1 |
| tb402 prevention | #1 |
| recommendations dvt | #1 |
| models development studies | #1 |
| p0424 | #1 |
| vkas lmwh | #1 |
| death category | #1 |
| pioped study study | #1 |
| simplified geneva score | #1 |
| thromboembolism 3 | #1 |
| dalteparin 6 months | #1 |
| uedvt terms | #1 |
| age multiple comorbidities | #1 |
| 53 amputations | #1 |
| khorana | #1 |
| departments pharmacological prophylaxis | #1 |
| pulmonary embolism fondaparinux | #1 |
| extended anticoagulation doacs | #1 |
| suspected perfusion scan | #1 |
| combined training gps | #1 |
| enoxaparin vkas treatment | #1 |
| obese hemophilic patients | #1 |
| 500 org | #1 |
| travel‐related venous thrombosis | #1 |
| heparin initial | #1 |
| patients deep | #1 |
| advanced malignancy | #1 |
| dvt 3 | #1 |
| pulmonary embolism basis | #1 |
| patients initial heparin | #1 |
| cart lower levels | #1 |
| role exclusion | #1 |
| death venous thromboembolism | #1 |
| probability lung scan | #1 |
| activecontrol placebo | #1 |
| patients antithrombotic prescriptions | #1 |
| reduceddose noacs stroke | #1 |
| 5‐snp scores | #1 |
| current practise | #1 |
| placebo 25mg apixaban | #1 |
| venous thromboembolism episode | #1 |
| symptomatic legs dvt | #1 |
| 2630 pilots | #1 |
| rnapc2 patients | #1 |
| ultrasound strategies patients | #1 |
| wells rules | #1 |
| cstatistic major bleeding | #1 |
| category fxainhibitors | #1 |
| somittrial | #1 |
| netherlands 5 years | #1 |
| rivaroxaban acute dvt | #1 |
| p0001 saline | #1 |
| vka netherlands | #1 |
| cdrscore | #1 |
| combination cdr | #1 |
| embolism sensitivity | #1 |
| pharmacological methods prophylaxis | #1 |
| symptomatic pts | #1 |
| 95 elevated ctni | #1 |
| idraparinux versus | #1 |
| nondiagnostic lung scan | #1 |
| survival lmwh | #1 |
| rnapc2 groups placebo | #1 |
| uesvt patients | #1 |
| ufh grade 1a | #1 |
| intravenous injections lmwh | #1 |
| rabinov | #1 |
| risk homozygous women | #1 |
| conventional therapy enoxaparin | #1 |
| undvt | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| platelets iqr | #1 |
| aged venous | #1 |
| variable d‐dimer thresholds | #1 |
| doac recipients | #1 |
| fondaparinux unfractionated | #1 |
| ipe expert radiologists | #1 |
| single‐detector row | #1 |
| initial treatment dvt | #1 |
| pulmonary embolism life | #1 |
| randomized studies efficacy | #1 |
| probability ventilation | #1 |
| vitamin antagonists time | #1 |
| category perelated death | #1 |
| vte day | #1 |
| false normal | #1 |
| cancer edoxaban | #1 |
| patients examiner | #1 |
| patients tb402 | #1 |
| probability cdr | #1 |
| oral rivaroxaban treatment | #1 |
| equinox study | #1 |
| bleeding risk treatment | #1 |
| women elevated levels | #1 |
| efficacy heparin therapy | #1 |
| prothrombin individuals | #1 |
| screening carriers | #1 |
| ultrasound compression ultrasound | #1 |
| standardintensity vkas doacs | #1 |
| acenocoumarol efficacy | #1 |
| diagnostic strategies strategies | #1 |
| diagnostic strategy primary | #1 |
| failure cip | #1 |
| enoxaparin primary efficacy | #1 |
| low levels ft4 | #1 |
| polyethylenglycolhirudin | #1 |
| poc test patients | #1 |
| study centre duration | #1 |
| anticoagulation period | #1 |
| prevalence coagulation | #1 |
| constans score | #1 |
| cancer patients ufh | #1 |
| ventilation scan chest | #1 |
| presentation 1 week | #1 |
| relevant major | #1 |
| 5 avidin infusion | #1 |
| comparison vidas assay | #1 |
| major bleeding cancer | #1 |
| 123362 | #1 |
| local radiologist | #1 |
| patients inherited thrombophilia | #1 |
| subsequent symptomatic cancer | #1 |
| vte occurred | #1 |
| wells cdr | #1 |
| silent dvt | #1 |
| cancer patients cvcs | #1 |
| patients enoxaparin vkas | #1 |
| combination ddimer testing | #1 |
| dalteparin vte treatment | #1 |
| 36 papers | #1 |
| thrombo‐embolic events | #1 |
| pulmonary embolism metaanalysis | #1 |
| subsequent diagnosis malignancy | #1 |
| symptomatic recurrent vte | #1 |
| normal dimer | #1 |
| idraparinux standard therapy | #1 |
| einsteindvt | #1 |
| test venography | #1 |
| easier monitoring | #1 |
| elevated fviii age | #1 |
| patients advanced prostate | #1 |
| double reports | #1 |
| enoxaparin tb402 | #1 |
| fetal loss miscarriage | #1 |
| ldf diagnosis | #1 |
| factor viii homocysteine | #1 |
| calfvein thrombi | #1 |
| obese controls difference | #1 |
| 5395 patients | #1 |
| warfarin cstatistic | #1 |
| 97 compression ultrasonography | #1 |
| 0·2 3633 patients | #1 |
| perelated death classification | #1 |
| 0·620·74 | #1 |
| duration heparin treatment | #1 |
| normal venogram | #1 |
| clinically relevant disease | #1 |
| realtime bmode ultrasonography | #1 |
| subcutaneous nadroparin placebo | #1 |
| abnormal ipg | #1 |
| compression ultrasonography patients | #1 |
| uesvt median | #1 |
| abelacimab | #1 |
| ctscan qscan | #1 |
| idrabiotaparinux idraparinux | #1 |
| nonhigh cdr | #1 |
| followup overt cancer | #1 |
| acute recurrent patients | #1 |
| subcutaneous idraparinux | #1 |
| safety 60 dose | #1 |
| principal safety | #1 |
| cdr normal | #1 |
| intravenous unfractionated | #1 |
| vte arterial | #1 |
| vte location | #1 |
| tests venography | #1 |
| safety idraparinux | #1 |
| progression svt | #1 |
| extended anticoagulation apixaban | #1 |
| impedance thrombophlebitis | #1 |
| fxainhibitors vka recipients | #1 |
| rabinovpaulin | #1 |
| fviii vte | #1 |
| cdr ddimer levels | #1 |
| oral apixaban treatment | #1 |
| vte fatal | #1 |
| rate recurrent | #1 |
| infections gentamicin | #1 |
| obstetric complications relatives | #1 |
| normotensive patients studies | #1 |
| heparin vitamin antagonist | #1 |
| ddimer result | #1 |
| 250 patients cancer | #1 |
| orthopedic surgery netherlands | #1 |
| normal levels fviii | #1 |
| ili score | #1 |
| 2 diagnostic management | #1 |
| placebo rnapc2 | #1 |
| revascularisation procedures patients | #1 |
| dvt anticoagulants | #1 |
| asymptomatic extension | #1 |
| heparin vitamin | #1 |
| united states rnapc2 | #1 |
| treatment cumulative incidence | #1 |
| members symptomatic carriers | #1 |
| patients mismatched scan | #1 |
| patients malignancy | #1 |
| idraparinux | #1 |
| presence venous thrombosis | #1 |
| fviii concentration | #1 |
| recurrent vte immobilization | #1 |
| early time recurrence | #1 |
| older patients cdr | #1 |
| anticoagulant treatment vte | #1 |
| types major bleeding | #1 |
| patients normal tests | #1 |
| adjusted dose ufh | #1 |
| 3 rfviia | #1 |
| excluding pulmonary | #1 |
| normal lung scan | #1 |
| prescriptionbased | #1 |
| botticelli dvt dose‐ranging | #1 |
| recurrence major bleeding | #1 |
| recurrent vte statin | #1 |
| rule exclusion | #1 |
| apixaban extended treatment | #1 |
| compression ultrasonography detection | #1 |
| inherited thrombophilia patients | #1 |
| 2479 relatives | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| feasibility venography | #1 |
| heparin acenocoumarol | #1 |
| presentation major | #1 |
| risk percentage points | #1 |
| vte risk day | #1 |
| travel venous thromboembolism | #1 |
| compression ultrasonography | #1 |
| deepvein thrombosis incidence | #1 |
| 9 incidence | #1 |
| echocardiography normotensive patients | #1 |
| lmwh users incidence | #1 |
| ivte clinical practice | #1 |
| dose daily edoxaban | #1 |
| proximal location ipe | #1 |
| suspected cdr | #1 |
| survival fondaparinux | #1 |
| apc resistance tests | #1 |
| 208791 | #1 |
| doubleheterozygotes | #1 |
| cancer 145 patients | #1 |
| unexplained dvt patients | #1 |
| year prophylaxis | #1 |
| cancer patients cdr | #1 |
| management study | #1 |
| simple diagnostic strategy | #1 |
| carriers thrombophilic defects | #1 |
| pulmonary angiography ultrasonography | #1 |
| relatives mutation | #1 |
| reocclusion antithrombotic drug | #1 |
| matisse dvt | #1 |
| positive vte | #1 |
| pulmonary embolism studies | #1 |
| apixaban randomized patients | #1 |
| bleeding rates quality | #1 |
| perelated death category | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| rivaroxaban lmwh vka | #1 |
| heparins data | #1 |
| heparin org 10172 | #1 |
| elevated fviii patients | #1 |
| protecht shr | #1 |
| relatives normal levels | #1 |
| respondents lmwh | #1 |
| lmwh delivery | #1 |
| elderly patients dvt | #1 |
| presenting location women | #1 |
| rnapc2 inhibition | #1 |
| travellers thrombosis | #1 |
| postthrombotic symptoms patients | #1 |
| risk pulmonary embolism | #1 |
| combination cdrscore | #1 |
| lmprovement | #1 |
| lowmolecularweight heparin 95 | #1 |
| venous thrombosis vwf | #1 |
| vitamin antagonists treatment | #1 |
| deep vein thrombosis | #1 |
| cstatistic model discrimination | #1 |
| rfviia 3 | #1 |
| lmwh departments | #1 |
| bleeding risk lmwh | #1 |
| abnormal vaginal bleeding | #1 |
| category death | #1 |
| recurrence bleeding risk | #1 |
| wound haematoma | #1 |
| cdr ddimer test | #1 |
| vte difference | #1 |
| prevention topic guidelines | #1 |
| referral basis | #1 |
| carriers relative risks | #1 |
| wells simplified | #1 |
| proportion pulmonary embolism | #1 |
| cancer patients patients | #1 |
| 750 μg l1 | #1 |
| venous thromboembolism edoxaban | #1 |
| patients protein deficiencies | #1 |
| idraparinux placebo | #1 |
| 8h flight | #1 |
| uesvt mortality | #1 |
| svt lmwh | #1 |
| presenting location vte | #1 |
| monoclonal antibodies apc | #1 |
| 00515 | #1 |
| amplify trial apixaban | #1 |
| prophylaxis crt | #1 |
| women factor leiden | #1 |
| cvc crt | #1 |
| laalleles | #1 |
| rule cdr | #1 |
| perfusion scan | #1 |
| sensitivity 100 percent | #1 |
| 0·2 edoxabantreated | #1 |
| acute treatment lmwh | #1 |
| absolute thrombotic risk | #1 |
| baseline characteristics duration | #1 |
| presenting vte location | #1 |
| mortality postthrombotic symptoms | #1 |
| loss subsequent pregnancy | #1 |
| quantitative ddimer testing | #1 |
| control anticardiolipin antibodies | #1 |
| heparins inhibition | #1 |
| deficiency proteins | #1 |
| relatives tafi levels | #1 |
| wellsrule | #1 |
| 5mg apixaban | #1 |
| gogh dvt trial | #1 |
| standard therapy months | #1 |
| pulmonary embolism tests | #1 |
| bleeding einstein | #1 |
| upper extremity uedvt | #1 |
| cdrscore combination | #1 |
| embolism randomized | #1 |
| vkas efficacy | #1 |
| hemorrhage heparin | #1 |
| standalone ddimer testing | #1 |
| 7268 patients suspected | #1 |
| fviii hyperhomocysteinemia | #1 |
| tb402 50 | #1 |
| 560 pharmacies | #1 |
| thrombophlebitis tomography | #1 |
| suspected symptomatic | #1 |
| safety outcome | #1 |
| systematic search cteph | #1 |
| incidence venous | #1 |
| riskstroponin | #1 |
| 547253 | #1 |
| patients uedvt uesvt | #1 |
| death vte studies | #1 |
| studies doac treatment | #1 |
| quantitative ddimer test | #1 |
| controlledstudy | #1 |
| 393 patients warfarin | #1 |
| sgs pretest probability | #1 |
| patients retropubic prostatectomy | #1 |
| aptt org 10172 | #1 |
| aptt org | #1 |
| pvoq | #1 |
| embolism wells | #1 |
| alternative diagnoses patients | #1 |
| practiceassistants | #1 |
| wellscdr | #1 |
| popliteal veins sensitivity | #1 |
| pulmonary embolism | #1 |
| idraparinux 6 months | #1 |
| selective ddimer thresholds | #1 |
| long haul flights | #1 |
| chest perfusion scintigraphy | #1 |
| procoagulant factors levels | #1 |
| vka share | #1 |
| longhaul flight | #1 |
| doacs factor | #1 |
| elderly outpatients combination | #1 |
| women edoxaban | #1 |
| thrombosis vitamin | #1 |
| pulmonary embolism cdr | #1 |
| wells rule exclusion | #1 |
| tsh antitpo | #1 |
| relevant bleeding | #1 |
| local radiologist experts | #1 |
| beneficial lmwh | #1 |
| flebography | #1 |
| heparinoid | #1 |
| cancer clinical presentation | #1 |
| severity clinical presentation | #1 |
| tomography angiography vte | #1 |
| avidin vte | #1 |
| falsenormal | #1 |
| ddimer test combination | #1 |
| ivte | #1 |
| thrombophilia patients doacs | #1 |
| clinically suspected uedvt | #1 |
| abdominal pelvic strategies | #1 |
| decisions duration | #1 |
| hokusaivte trial patients | #1 |
| phase doacs | #1 |
| lmwh immobilization | #1 |
| lmwhs 95 | #1 |
| symptomatic venous | #1 |
| ifngamma pselectin | #1 |
| idraparinux vitamin antagonist | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| 7268 patients | #1 |
| simplified wells rule | #1 |
| unexplained dvt | #1 |
| cancer patients cancer | #1 |
| failure diagnostic management | #1 |
| heparins cancer patients | #1 |
| antidote vitamin | #1 |
| elevated ctni patients | #1 |
| coagulation clinical | #1 |
| thiazoles venous | #1 |
| outpatients symptomatic dvt | #1 |
| idraparinux patients | #1 |
| avidin idrabiotaparinux | #1 |
| molecular weight fondaparinux | #1 |
| achieved inr patients | #1 |
| dalteparin major bleeding | #1 |
| 50 rivaroxaban | #1 |
| edoxaban risk factors | #1 |
| sustained antithrombotic effects | #1 |
| clinical probability exclusion | #1 |
| early discharge strategies | #1 |
| failure rate efficiency | #1 |
| org aptt | #1 |
| thromboembolism treated | #1 |
| warfarin cancer patients | #1 |
| 12 kg1 enoxaparin | #1 |
| study ecq | #1 |
| reported incidence vte | #1 |
| lowmolecularweight heparin treatment | #1 |
| 3 idraparinux | #1 |
| ldf cus | #1 |
| rfviia idraparinux | #1 |
| distal clots | #1 |
| treatment experimental thrombosis | #1 |
| proportion 75 years | #1 |
| association travel | #1 |
| questionnaires thrombosis | #1 |
| suspected deep | #1 |
| vitamin antagonist patients | #1 |
| 6 months avidin | #1 |
| rivaroxaban replacement | #1 |
| hyperhomocysteinemia relatives | #1 |
| vka treatment treatment | #1 |
| oral anticoagulants phase | #1 |
| probability normal | #1 |
| enoxaparin vkas | #1 |
| acenocoumarol initial treatment | #1 |
| 15 lmwh | #1 |
| standard therapy rivaroxaban | #1 |
| exclusion pulmonary | #1 |
| desogestrelcontaining coagulation factors | #1 |
| bmi fondaparinux | #1 |
| dimer result | #1 |
| lmwh acute treatment | #1 |
| common alternative diagnoses | #2 |
| surgical casts | #2 |
| pentasaccharide fondaparinux | #2 |
| 95 dvt | #2 |
| ate cancer patients | #2 |
| incidental vte | #2 |
| ageadjusted ddimer testing | #2 |
| patients low probability | #2 |
| blood coagulation rnapc2 | #2 |
| vte elevated fviii | #2 |
| statins recurrent vte | #2 |
| subsegmental emboli | #2 |
| tinaquant vidas | #2 |
| c1173t dimorphism | #2 |
| secondary efficiency | #2 |
| extended constans score | #2 |
| 95 cancer patients | #2 |
| enoxaparin difference | #2 |
| clinically suspected | #2 |
| death vte | #2 |
| single administration tb402 | #2 |
| medscape | #2 |
| hellp syndrome prevalence | #2 |
| clinical probability estimate | #2 |
| n832 | #2 |
| exclusion pulmonary embolism | #2 |
| rnapc2 | #2 |
| screening fvl | #2 |
| central localization | #2 |
| comparator individuals 95 | #2 |
| 8292 patients | #2 |
| alife study | #2 |
| hmb primary outcome | #2 |
| rivaroxaban 30 bid | #2 |
| antagonists vka | #2 |
| primary healthcare secondary | #2 |
| cancer addition | #2 |
| hyperglycemia diagnosis | #2 |
| composite scores area | #2 |
| amuse strategy | #2 |
| safety pravastatin therapy | #2 |
| pravastatin therapy children | #2 |
| primary hospitalbased strategies | #2 |
| simplired test | #2 |
| cancer recurrent vte | #2 |
| rule combined | #2 |
| vte 12 | #2 |
| heparin nadroparin | #2 |
| levothyroxine exposure | #2 |
| heparin administered | #2 |
| interleukin‐10 response | #2 |
| hokusai vte | #2 |
| life treatment duration | #2 |
| oral direct inhibitors | #2 |
| intrinsic cascade | #2 |
| 17 apixaban | #2 |
| suspected upper | #2 |
| warfarintreated | #2 |
| treatment ttr | #2 |
| bleeding rate patients | #2 |
| annual incidences | #2 |
| vte orthopedic surgery | #2 |
| gcpg | #2 |
| subcutaneous length | #2 |
| diagnostic lung | #2 |
| rfviia injection rfviia | #2 |
| undiagnosed malignancy | #2 |
| 3306 patients | #2 |
| thromboembolism thrombophilia | #2 |
| sustained antithrombotic | #2 |
| prothrombin pulmonary embolism | #2 |
| 8 wk risk | #2 |
| gauge plethysmography | #2 |
| crnm bleeds | #2 |
| ufh survival | #2 |
| raskob | #2 |
| sr34006 | #2 |
| treated edoxaban | #2 |
| embolism safely | #2 |
| failure rate strategy | #2 |
| embolism deep | #2 |
| endogenous activated protein | #2 |
| analysis venous | #2 |
| suspected pulmonary | #2 |
| 20210a mutations | #2 |
| risk khorana | #2 |
| efficiency original score | #2 |
| blood coagulation inhibition | #2 |
| uedvt efficiency | #2 |
| plasma concentrations endotoxin | #2 |
| uedvt performance | #2 |
| enoxaparin warfarin | #2 |
| rivaroxaban thiazoles | #2 |
| ultrasonography patients | #2 |
| absolute incidence | #2 |
| arterial thrombotic disease | #2 |
| relevant patient subgroups | #2 |
| incidence recurrent | #2 |
| standardised time intervals | #2 |
| healthcare settings findings | #2 |
| compression doppler | #2 |
| pregnancy venous thrombosis | #2 |
| patients peripheral graft | #2 |
| impedance plethysmography patients | #2 |
| fviii increased risk | #2 |
| pregnancy coc | #2 |
| protein rnapc2 | #2 |
| received edoxaban | #2 |
| vidas assay | #2 |
| thyroid hormone coagulation | #2 |
| primary efficacy outcome | #2 |
| fibrinolysis pentoxifylline | #2 |
| apixaban enoxaparin warfarin | #2 |
| heparin treatment influenza | #2 |
| simplified wells | #2 |
| travel venous | #2 |
| mutations cleavage sites | #2 |
| exclude pulmonary | #2 |
| bleeding edoxaban | #2 |
| mutation 35 | #2 |
| normal ddimer test | #2 |
| ventilation scanning | #2 |
| patients prior vte | #2 |
| principal safety outcome | #2 |
| nematode anticoagulant | #2 |
| test cancer | #2 |
| major bleeding intermediate | #2 |
| coagulation fibrinolytic | #2 |
| pharmacological strategies | #2 |
| intermediate phenotype vte | #2 |
| f5 r506q | #2 |
| hemorr2hages atria scores | #2 |
| thrombosis normal | #2 |
| uptake noacs | #2 |
| risk deep | #2 |
| ufh 6 months | #2 |
| heparin compounds | #2 |
| cha2ds2vasc nri | #2 |
| computed venous | #2 |
| mutations propeptide | #2 |
| hokusai vtecancer study | #2 |
| euro138 | #2 |
| brain metastases doacs | #2 |
| fvl carriers carriers | #2 |
| influenza prothrombotic state | #2 |
| limits cancer | #2 |
| employees longhaul flight | #2 |
| serum tnf activity | #2 |
| secondary strategies | #2 |
| n1423 | #2 |
| impedance plethysmography diagnosis | #2 |
| concomitant thrombophilic | #2 |
| plasma d‐dimer concentration | #2 |
| risk anticoagulation therapy | #2 |
| recombinant nematode | #2 |
| thrombophilic defects risk | #2 |
| biomarkers casecontrol studies | #2 |
| anticoagulated patients permanent | #2 |
| deficiencies proteins | #2 |
| recurrent deep | #2 |
| pulmonary embolism efficacy | #2 |
| vitamin antagonists quality | #2 |
| patients hemorr2hages | #2 |
| decision rule | #2 |
| scan normal | #2 |
| coagulation factors prolactin | #2 |
| sspe patients patients | #2 |
| major clinically | #2 |
| lmwh users | #2 |
| embolism primary | #2 |
| dimer thresholds | #2 |
| clinical pretest probability | #2 |
| recurrent vte risk | #2 |
| adapted ddimer thresholds | #2 |
| nonpermanent heart failure | #2 |
| idraparinux vitamin | #2 |
| duration anticoagulant treatment | #2 |
| major bleeding recurrent | #2 |
| quality warfarin treatment | #2 |
| pulmonary embolism purpose | #2 |
| recombinant hirudin cgp | #2 |
| cdr variables cdr | #2 |
| lowmolecularweight heparin women | #2 |
| bleeding occurred | #2 |
| global public awareness | #2 |
| ddimer determination | #2 |
| efficiency diagnostic strategies | #2 |
| months 25 | #2 |
| negative ageadjusted ddimer | #2 |
| endotoxininduced activation coagulation | #2 |
| presentation dvt | #2 |
| thromboinflammation cardiovascular disease | #2 |
| beta‐receptor blockade | #2 |
| venous thrombophlebitis | #2 |
| outcome symptomatic | #2 |
| wells cdr cdr | #2 |
| incidental venous | #2 |
| crd42017056309 | #2 |
| symptomatic outpatients | #2 |
| influenza coagulation | #2 |
| current clinical challenges | #2 |
| years 36 | #2 |
| venographically | #2 |
| wells cdr patients | #2 |
| major bleeding edoxaban | #2 |
| fibrinolytic proteins | #2 |
| pulmonary embolism asthma | #2 |
| hospitalbased strategies | #2 |
| ddimer assay | #2 |
| heparin effective | #2 |
| uedvt cancer patients | #2 |
| duration anticoagulant | #2 |
| venous thromboembolism enoxaparin | #2 |
| rnapc2 doses | #2 |
| exposure flights | #2 |
| major bleeding cindexes | #2 |
| bleeding complications treatment | #2 |
| angioplasty clopidogrel | #2 |
| computerized impedance | #2 |
| lower clinical utility | #2 |
| relation coagulation factors | #2 |
| 6 months scores | #2 |
| recurrence thromboembolism | #2 |
| administration rviia | #2 |
| score dimer | #2 |
| clinical prediction model | #2 |
| performance constans rule | #2 |
| vte svt | #2 |
| women therapeutic doses | #2 |
| factor iia | #2 |
| 95 comparator individuals | #2 |
| treated anticoagulants | #2 |
| patients oral factor | #2 |
| amadeus study | #2 |
| nct00633893 | #2 |
| fibrinolysis influenza | #2 |
| normohomocysteinemic relatives | #2 |
| patients abi measurement | #2 |
| measurement ankle brachial | #2 |
| mdct reference standard | #2 |
| patients khorana score | #2 |
| treatment deep | #2 |
| graft occlusion patients | #2 |
| cdr wells cdr | #2 |
| vte 1000 personyears | #2 |
| rule proportion | #2 |
| levels coagulation factors | #2 |
| 95 0·2 | #2 |
| prolactin relation | #2 |
| efficiency strategy | #2 |
| referred patients secondary | #2 |
| lmwh efficacy | #2 |
| resource utilisation treatment | #2 |
| vitamin antagonist rivaroxaban | #2 |
| venous | #2 |
| apixaban lmwh vka | #2 |
| suspected pulmonary embolism | #2 |
| coumarin sensitivity | #2 |
| plasmin activity inhibition | #2 |
| inflammation neutrophils thrombosis | #2 |
| age‐adjusted d‐dimer testing | #2 |
| vein compressibility | #2 |
| regression pravastatin | #2 |
| thrombophilic disorders | #2 |
| acquired antithrombin | #2 |
| model cancer patients | #2 |
| hasbled score hemorr2hages | #2 |
| mild risk factor | #2 |
| low‐molecular‐weight heparin | #2 |
| events severe | #2 |
| khorana protecht | #2 |
| atria hemorr2hages | #3 |
| idrabiotaparinux warfarin | #3 |
| dvt major | #3 |
| gestalt probability | #3 |
| protein thrombophilia | #3 |
| primary wells rule | #3 |
| heparin heparin | #3 |
| pulmonary embolism models | #3 |
| platelet agents | #3 |
| clinical models patients | #3 |
| inhibition blood coagulation | #3 |
| pulmonary embolism primary | #3 |
| venous thromboembolism | #3 |
| prolactin controls | #3 |
| wells rule dvt | #3 |
| vte denmark | #3 |
| thombosis | #3 |
| dimer blood | #3 |
| heparins cancer | #3 |
| combination wells score | #3 |
| ddimer assays | #3 |
| vte performance | #3 |
| plethysmography impedance | #3 |
| safely | #3 |
| influence heparins | #3 |
| simplified wells specificity | #3 |
| lmwh | #3 |
| patients wells | #3 |
| ipe cancer patients | #3 |
| stable acute | #3 |
| recombinant hirudin rhir | #3 |
| prevalence hemostatic abnormalities | #3 |
| cohort study employees | #3 |
| patients 6 months | #3 |
| svt vte | #3 |
| outcome venous | #3 |
| vte 3 | #3 |
| thrombophilic defect | #3 |
| standard therapy treatment | #3 |
| desogestrelcontaining | #3 |
| dvt systematic differences | #3 |
| diagnosis pulmonary embolism | #3 |
| “gestalt | #3 |
| patients venous | #3 |
| healthy donor fmt | #3 |
| apc protective | #3 |
| older children vte | #3 |
| mutation venous | #3 |
| 95 wells rule | #3 |
| subcutaneous lmwh | #3 |
| pulmonary embolism‐related death | #3 |
| factor viiic | #3 |
| venous thrombosis cancer | #3 |
| definition perelated death | #3 |
| vte major burden | #3 |
| approaches primary | #3 |
| incidence enoxaparin | #3 |
| pad smokers | #3 |
| nct00643201 | #3 |
| outpatient treatment dvt | #3 |
| antithrombin iii concentrate | #3 |
| presenting location | #3 |
| predictable pharmacokinetics | #3 |
| composite stroke | #3 |
| 02011 | #3 |
| multiple comorbidities polypharmacy | #3 |
| studies hemorrhage | #3 |
| adult patients vte | #3 |
| thromboembolism low | #3 |
| single diagnostic | #3 |
| failurerate | #3 |
| 6575 years | #3 |
| coagulation influence | #3 |
| venous thrombosis travel | #3 |
| selectine | #3 |
| venous arterial | #3 |
| hokusai‐vte | #3 |
| venous thrombosis positive | #3 |
| mechanisms heparin | #3 |
| cancer active cancer | #3 |
| compensated dic | #3 |
| capillary blood sample | #3 |
| diagnosis deep | #3 |
| hasbled | #3 |
| ddimer threshold | #3 |
| cancer patients ate | #3 |
| ultrasonography strategies | #3 |
| 20210ga | #3 |
| tfindependent | #3 |
| axa activity | #3 |
| discontinuation ufh | #3 |
| enoxaparin follow | #3 |
| bleeding major | #3 |
| pph lmwh | #3 |
| rnapc2 fviia | #3 |
| activecontrol | #3 |
| negative predictive proportion | #3 |
| hf severity risk | #3 |
| thrombophlebitis treatment | #3 |
| recurrent thromboembolic | #3 |
| coagulation air travel | #3 |
| endogenous apc | #3 |
| treatment vka | #3 |
| patients ft4 level | #3 |
| treatment vte recurrence | #3 |
| diagnosis pulmonary | #3 |
| age annual incidence | #3 |
| dalteparin difference | #3 |
| safely exclude | #3 |
| deep vein | #3 |
| cardiac troponine | #3 |
| incidental pulmonary embolism | #3 |
| therapy venous | #3 |
| einstein studies | #3 |
| einstein patients | #3 |
| nadroparin placebo | #3 |
| studies cus strategies | #3 |
| dose reduction edoxaban | #3 |
| cancer patients ipe | #3 |
| 3633 patients | #3 |
| ft4 risk | #3 |
| efficacy heparin | #3 |
| embolism‐related | #3 |
| patients proximalvein thrombosis | #3 |
| idiopathic venous | #3 |
| tinaquant assay | #3 |
| low probability models | #3 |
| idrabiotaparinux | #3 |
| introduction mdct | #3 |
| favour lmwh | #3 |
| treatment lowmolecularweight heparin | #3 |
| female hemorrhage humans | #3 |
| venous thromboembolism thrombophilia | #3 |
| monoclonal replacement | #3 |
| revised geneva efficiency | #3 |
| vein thrombosis | #3 |
| lmwh pph | #3 |
| gestalt 95 | #3 |
| travel venous thrombosis | #3 |
| vte low | #3 |
| safely excluded | #3 |
| heparin edoxaban | #3 |
| ventilation scan | #3 |
| fxiaso | #3 |
| pulmonary embolism gestalt | #3 |
| products follow | #3 |
| factors prothrombin | #3 |
| 12month study period | #3 |
| bleeding 3 | #3 |
| extensive screening | #3 |
| normal result | #3 |
| einstein dvt | #3 |
| strategies efficiency | #3 |
| dip placebo | #3 |
| dvt primary | #3 |
| knee factor | #3 |
| warfarin subgroup | #3 |
| crt cancer patients | #3 |
| safety acenocoumarol | #3 |
| placebo n4 | #3 |
| vte venous thrombosis | #3 |
| primary rule | #3 |
| topic heparin heparin | #3 |
| treatment vitamin antagonists | #3 |
| death clinical studies | #3 |
| cdr combination | #3 |
| detection dvt | #3 |
| patients gastrointestinal cancer | #3 |
| impedance predictive | #3 |
| thiophenes venous | #3 |
| ctnt risk stratification | #3 |
| time venous thrombosis | #3 |
| patients ultrasonography | #3 |
| tb‐402 | #3 |
| lowmolecularweight heparin placebo | #3 |
| chemotherapy prophylaxis | #3 |
| proximalvein thrombosis | #3 |
| 100 years year | #3 |
| wells rule gestalt | #3 |
| normal ctnt presentation | #3 |
| patients incidental vte | #3 |
| users incidence | #3 |
| outpatients dvt | #3 |
| administration rnapc2 | #3 |
| treatment low | #3 |
| prevalence avws | #3 |
| alternative diagnoses | #3 |
| iii deficiency | #3 |
| recurrence thrombophlebitis | #3 |
| cancer randomised trials | #3 |
| sensitivity compression | #3 |
| baseline values placebo | #3 |
| intravenous loading dose | #3 |
| lowmolecularweight humans length | #3 |
| incidence total vte | #3 |
| venous thromboembolism apixaban | #3 |
| 3month vte incidence | #3 |
| dvt hip | #3 |
| dvt einstein | #3 |
| probability dimer | #3 |
| 3month incidence | #3 |
| female humans inhibitors | #3 |
| patients 6575 years | #3 |
| subcutaneous fondaparinux | #3 |
| thromboembolism background | #3 |
| patients venography | #3 |
| oral hormonal cross | #3 |
| rfviia injection | #4 |
| venous thromboembolism patients | #4 |
| episode venous | #4 |
| protecht | #4 |
| thromboembolism occurred | #4 |
| thromboembolism treatment | #4 |
| vte highincome countries | #4 |
| abdomen relationship | #4 |
| clinically relevant bleeding | #4 |
| diagnostic management | #4 |
| lmwh female heparin | #4 |
| received warfarin | #4 |
| criteria dose reduction | #4 |
| vte treatment patients | #4 |
| thrombophilia 95 | #4 |
| nct00571649 | #4 |
| mbe patients | #4 |
| “reversal | #4 |
| advanced cancer 95 | #4 |
| netherlands pulmonary | #4 |
| thrombosis uedvt | #4 |
| activation fibrinolytic | #4 |
| vitamin antagonist treatment | #4 |
| chinese korean ethnicity | #4 |
| lowmolecularweight heparin | #4 |
| point dimer | #4 |
| thrombosis deep | #4 |
| ultrasonography venous | #4 |
| primary failure rate | #4 |
| patient category | #4 |
| extended treatment | #4 |
| women normal levels | #4 |
| patient education treatment | #4 |
| embolism dimer | #4 |
| vte global | #4 |
| cleavage sites apc | #4 |
| thromboembolism study | #4 |
| embolism tomography | #4 |
| ddimer assay patients | #4 |
| impedance plethysmography | #4 |
| rule pulmonary | #4 |
| serial impedance plethysmography | #4 |
| population rivaroxaban | #4 |
| 0651 | #4 |
| global disease burden | #4 |
| enoxaparin female humans | #4 |
| vte global burden | #4 |
| enoxaparin day | #4 |
| tinaquant | #4 |
| patients dimer | #4 |
| thrombosis symptomatic | #4 |
| 335 patients | #4 |
| lmwhs standard heparin | #4 |
| fibrin generation test | #4 |
| warfarin 3 months | #4 |
| serial impedance | #4 |
| thromboembolism systematic | #4 |
| estrogen therapy patients | #4 |
| apixaban efficacy | #4 |
| hemorr2hages | #4 |
| postthrombotic symptoms | #4 |
| global burden vte | #4 |
| travel thrombosis | #4 |
| oral rivaroxaban | #4 |
| chemotherapy vte prophylaxis | #4 |
| 150 microg levonorgestrel | #4 |
| pregnancies carriers | #4 |
| thrombosis ischemic stroke | #4 |
| proximal patients | #4 |
| patients edoxaban | #4 |
| diagnostic prediction models | #4 |
| procoagulant factors | #4 |
| total vte | #4 |
| safety pravastatin | #4 |
| clot resolution | #4 |
| rviia thrombin generation | #4 |
| embolism roc | #4 |
| chromogenic compounds | #4 |
| preexisting heparin | #4 |
| bleeding anticoagulants | #4 |
| venography patients | #4 |
| series venograms | #4 |
| negative point | #4 |
| patients venous thromboembolism | #4 |
| thromboembolism factor | #4 |
| gramnegative bacteria humans | #4 |
| contraindications treatment | #4 |
| patients alternative diagnosis | #4 |
| cancer vwf | #4 |
| life duration | #4 |
| 3587 | #4 |
| disease burden vte | #4 |
| daily netilmicin | #4 |
| dutch orthopedic | #4 |
| hyperhomocysteinemic relatives | #4 |
| risk vkas | #4 |
| thromboembolism arterial | #4 |
| patients submassive | #4 |
| rivaroxaban 20 | #4 |
| recurrent vte months | #4 |
| refuted | #4 |
| control anticoagulation | #4 |
| thromboembolism vitamin | #4 |
| probability prospective | #4 |
| chads2 p0001 | #4 |
| levels ft4 | #4 |
| chemotherapy shr | #4 |
| primary pulmonary embolism | #4 |
| dimer assays | #4 |
| clot lysis patients | #4 |
| questionnaires venous | #4 |
| diagnostic management strategies | #4 |
| coagulation factors risk | #4 |
| arterial thrombotic | #4 |
| lowmolecular weight heparins | #4 |
| ageadjusted cutoff patients | #4 |
| predilution postdilution | #4 |
| 150 microg desogestrel | #4 |
| noacs netherlands | #4 |
| vte netherlands | #4 |
| thrombophilic families | #4 |
| disease vte | #4 |
| 35±4 | #4 |
| embolism background | #4 |
| coagulation endotoxin | #4 |
| vitamin antagonists patients | #4 |
| risk occult cancer | #4 |
| measurement abi | #4 |
| vka treatment | #4 |
| symptomatic deep | #4 |
| hemostatic profile | #4 |
| women apc resistance | #4 |
| thrombosis air | #4 |
| vitamin antagonists | #4 |
| venous thrombosis levels | #4 |
| prophylaxis lmwh | #4 |
| leiden carriers | #4 |
| noacs cancer patients | #4 |
| patients clinically | #4 |
| edoxaban patients | #4 |
| patients fondaparinux | #4 |
| patients nonpermanent | #4 |
| doac studies | #4 |
| patients primary healthcare | #4 |
| treatment unfractionated heparin | #4 |
| lmwh cancer patients | #4 |
| death survey | #4 |
| vte total | #4 |
| amadeus trial | #4 |
| idiopathic venous thrombosis | #4 |
| patients crcl 60 | #4 |
| diagnosis uedvt | #4 |
| dose noacs | #4 |
| 10172 | #4 |
| 6 months prophylaxis | #4 |
| sankyo | #4 |
| normal ctpa | #5 |
| daiichi sankyo | #5 |
| endotoxin chimpanzees | #5 |
| specificity thrombophlebitis | #5 |
| inhibition plasminogen activation | #5 |
| thromboembolism idraparinux | #5 |
| iii plasminogen | #5 |
| patients parenteral anticoagulants | #5 |
| diagnosis questionnaire | #5 |
| endotoxin testing | #5 |
| dimer combination | #5 |
| 2 rules | #5 |
| deepvein thrombosis | #5 |
| secondary dvt | #5 |
| pregnancy pph | #5 |
| treatment fondaparinux | #5 |
| cdr patients | #5 |
| clinical probability | #5 |
| elevated plasma level | #5 |
| dvt prevalence | #5 |
| thromboembolism thrombosis | #5 |
| gestalt | #5 |
| coc pregnancy | #5 |
| rivaroxaban enoxaparin vka | #5 |
| outcome major | #5 |
| embolism reproducibility | #5 |
| day rivaroxaban | #5 |
| vte patients cancer | #5 |
| thrombosis upper | #5 |
| endogenous activated | #5 |
| risk prediction scores | #5 |
| low‐molecular‐weight | #5 |
| coronary angioplasty angioplasty | #5 |
| fh patients cvd | #5 |
| adjusted dimer | #5 |
| pulmonary embolism patients | #5 |
| asymptomatic carriers mutation | #5 |
| secondary venous thrombosis | #5 |
| thromboembolism studies | #5 |
| repeated ultrasonography | #5 |
| preschool contraceptives | #5 |
| thrombophlebitis ultrasonography | #5 |
| severe pph women | #5 |
| fviia rnapc2 | #5 |
| bleeding cancer | #5 |
| upper extremity thrombosis | #5 |
| suspected uedvt | #5 |
| patients pulmonary embolism | #5 |
| fviii families | #5 |
| molecularweight heparin | #5 |
| lmwh recommended | #5 |
| thromboembolism | #5 |
| sensitivity negative predictive | #5 |
| hirudin treatment | #5 |
| ventricular dysfunction echocardiography | #5 |
| medea study | #5 |
| low molecularweight humans | #5 |
| women warfarin | #5 |
| phlebography plethysmography | #5 |
| heparin compared | #5 |
| patients recurrent dvt | #5 |
| antithrombotic drug treatment | #5 |
| vte 6 | #5 |
| outpatients hospital | #5 |
| pad smoking | #5 |
| netilmicin patients | #5 |
| 8491 | #5 |
| venous thromboembolism studies | #5 |
| diagnostic strategies | #5 |
| thrombosis leg | #5 |
| burden vte | #5 |
| exclusion venous thromboembolism | #5 |
| patients wells score | #5 |
| thrombosis primary | #5 |
| cgp 39393 | #5 |
| predilution | #5 |
| patients subtherapeutic | #5 |
| compression ultrasound | #5 |
| cancer strategy | #5 |
| previous venous thromboembolism | #5 |
| lmwh incidence | #5 |
| consensus strategy | #5 |
| vte factor | #5 |
| transfusion blood loss | #5 |
| vka patients | #5 |
| recurrent dvt patients | #5 |
| 8292 | #5 |
| clinical presentation clinical | #5 |
| clinical probability assessment | #5 |
| patients superficial thrombophlebitis | #5 |
| treatment acute dvt | #5 |
| panwards | #5 |
| factor leiden 95 | #5 |
| incidence prognostic significance | #5 |
| efficiency patients | #5 |
| ft4 level | #5 |
| southern latin america | #5 |
| isolated calfvein thrombosis | #5 |
| hokusai | #5 |
| amplify | #6 |
| lmwh cancer | #6 |
| probability pulmonary | #6 |
| funding bayer | #6 |
| 39393 | #6 |
| factor leiden carriers | #6 |
| warfarin venous thromboembolism | #6 |
| patients suspected | #6 |
| efficiency proportion | #6 |
| svt extension | #6 |
| leiden | #6 |
| proportion cancer patients | #6 |
| 12month cumulative incidence | #6 |
| assay fibrin | #6 |
| thrombosis guidelines | #6 |
| severe antithrombin | #6 |
| endotoxininduced activation | #6 |
| duration rivaroxaban | #6 |
| subcutaneous nadroparin | #6 |
| repeatedly normal | #6 |
| synthetic pentasaccharides | #6 |
| treatment ufh | #6 |
| patients uedvt | #6 |
| simplired dimer | #6 |
| enoxaparin incidence | #6 |
| perioperative blood loss | #6 |
| thrombophilic defects | #6 |
| lmwh users users | #6 |
| compression stockings patients | #6 |
| effects levonorgestrel | #6 |
| patients lowmolecularweight heparin | #6 |
| subjects vte | #6 |
| neoplasms pulmonary embolism | #6 |
| 393 patients | #6 |
| 049 95 | #6 |
| vte controls | #6 |
| anticoagulant treatment | #6 |
| effects ufh | #6 |
| cancer primary patients | #6 |
| c1173 | #6 |
| recurrent pulmonary | #6 |
| incidence recurrence | #6 |
| combined utility | #6 |
| oral anticoagulants dabigatran | #6 |
| severe dic | #6 |
| patients proximal | #6 |
| thromboembolism bleeding | #6 |
| vte cancer | #6 |
| ultrasonography normal | #6 |
| vte anticoagulant treatment | #6 |
| treatment svt | #6 |
| isolated deficiencies | #6 |
| venograms | #6 |
| treatment pulmonary embolism | #6 |
| stressinduced hyperglycaemia | #6 |
| fviia inhibition | #6 |
| dvt trial | #6 |
| rate major bleeding | #6 |
| endotoxin assays | #6 |
| dabigatran etexilate dabigatran | #6 |
| elisapositive | #6 |
| daily gentamicin | #6 |
| low absolute risk | #6 |
| oral edoxaban | #6 |
| d‐dimer testing | #6 |
| risk increasing levels | #6 |
| selective beta | #6 |
| embolism pulmonary | #6 |
| dimer cut | #6 |
| conventional therapy treatment | #6 |
| patients anticoagulation clinic | #6 |
| women hyperhomocysteinemia | #6 |
| 10±4 | #6 |
| patients tests | #6 |
| embolism ventricular | #6 |
| outcome occurred | #6 |
| initial heparin treatment | #6 |
| dalteparin dose | #6 |
| grade 1a ufh | #6 |
| levonorgestrel desogestrel | #6 |
| vka | #6 |
| pembqol questionnaire | #6 |
| patients pulmonary angiography | #6 |
| symptomatic legs | #6 |
| patients iohexol | #6 |
| edoxaban efficacy | #6 |
| myocardial infarction ctni | #6 |
| clinically relevant subgroups | #6 |
| patients diagnostic | #6 |
| pulmonary embolism presence | #6 |
| wells rule | #6 |
| risk khorana score | #6 |
| apixaban treatment dose | #6 |
| arterial cardiovascular | #6 |
| anticoagulants hemorrhage | #6 |
| standardized morbidity ratio | #6 |
| blood coagulation mechanism | #6 |
| anticoagulants female | #6 |
| treatment intermittent claudication | #6 |
| subcutaneous low | #6 |
| patients factor mutation | #6 |
| ft4 patients | #6 |
| diagnostic workup | #6 |
| symptoms intermittent claudication | #6 |
| prevalence vte | #6 |
| antagonists treatment | #6 |
| fixeddose regimen | #6 |
| 597939 | #7 |
| pulmonary embolism sensitivity | #7 |
| diagnosis venous thrombosis | #7 |
| aspirin combined | #7 |
| venous thrombosis treatment | #7 |
| tnf injection | #7 |
| negative ddimer test | #7 |
| dvt ipg | #7 |
| silent pulmonary embolism | #7 |
| lung scan | #7 |
| diagnostic suspicion | #7 |
| factor female humans | #7 |
| thromboembolism vte | #7 |
| etexilate oral | #7 |
| perelated death | #7 |
| relation levels | #7 |
| 220 dabigatran | #7 |
| major bleeding vkas | #7 |
| vitamin antagonists vka | #7 |
| unselected women | #7 |
| major bleeding rate | #7 |
| patients standard heparin | #7 |
| thrombophlebitis adolescent | #7 |
| carriers venous thromboembolism | #7 |
| protein protein deficiencies | #7 |
| 680 | #7 |
| relation prolactin levels | #7 |
| primary efficacy | #7 |
| blood coagulation humans | #7 |
| combination ipg | #7 |
| leg ultrasonography | #7 |
| recurrent dvt | #7 |
| placebo rivaroxaban | #7 |
| neoplasms pulmonary | #7 |
| heparin org | #7 |
| administration bsf | #7 |
| prothrombin risk | #7 |
| noncompressibility | #7 |
| vka therapy | #7 |
| carriers defects | #7 |
| thrombophilia pregnancy loss | #7 |
| inhibitor apixaban | #7 |
| treatment doac | #7 |
| statin treatment risk | #7 |
| presence cteph | #7 |
| antithrombin protein | #7 |
| day initial treatment | #7 |
| general practitioners guideline | #7 |
| ufh treatment | #7 |
| specific antidotes | #7 |
| major bleeding | #7 |
| tb402 | #7 |
| thromboembolism adult | #7 |
| coagulation humans | #7 |
| spiral sensitivity | #7 |
| deepvein thrombosis patients | #7 |
| plasma levels ifngamma | #7 |
| incidence recurrent vte | #7 |
| rates edoxaban | #7 |
| nondiagnostic lung scans | #7 |
| anticoagulant parameters | #7 |
| primary dvt | #7 |
| levels factor viii | #7 |
| phenprocoumon polymorphism | #7 |
| negative predictive npv | #7 |
| proportion older patients | #7 |
| ottawa score | #7 |
| vte cancer diagnosis | #7 |
| arterial cardiovascular disease | #7 |
| mutations factor viii | #7 |
| thromboembolism total | #7 |
| stockings control | #7 |
| doppler skin | #7 |
| mpc1609 | #7 |
| embolism prospective | #7 |
| rivaroxaban 10 | #7 |
| dimer tests | #8 |
| agnelli | #8 |
| deficiency antithrombin | #8 |
| severe preeclampsia patients | #8 |
| treatment venous thrombosis | #8 |
| proximal deep | #8 |
| anticoagulants antineoplastic | #8 |
| increased fibrinolytic | #8 |
| oral apixaban | #8 |
| lmwh grade 1a | #8 |
| administration low | #8 |
| objectively confirmed | #8 |
| oac adherence | #8 |
| 1599 patients | #8 |
| point ultrasonography | #8 |
| leiden prothrombin | #8 |
| 150 enoxaparin | #8 |
| oral glucocorticoids risk | #8 |
| thrombosis prophylaxis | #8 |
| years cumulative incidence | #8 |
| enoxaparin vka | #8 |
| inherited thrombophilic | #8 |
| unprovoked vte patients | #8 |
| thrombosis adolescent | #8 |
| probability lung | #8 |
| patients extended anticoagulation | #8 |
| nondiagnostic scan | #8 |
| contrast venography | #8 |
| testing rule | #8 |
| vte score | #8 |
| tests pulmonary | #8 |
| wells scores | #8 |
| euro55 | #8 |
| overt cancer | #8 |
| prevention vte | #8 |
| optimal intensity | #8 |
| fxi aso | #8 |
| pvoct | #8 |
| recurrent vte mb | #8 |
| bnp ctnt | #8 |
| discontinuation anticoagulant treatment | #8 |
| international organisations | #8 |
| initial heparin | #8 |
| consecutive outpatients | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| physicians stockings | #8 |
| current approach | #8 |
| low clinical probability | #8 |
| arg506 factor | #8 |
| patients symptomatic vte | #8 |
| compression surveys | #8 |
| persistent risk factors | #8 |
| heparin vitamin antagonists | #8 |
| symptomatic deepvein thrombosis | #8 |
| ageadjusted ddimer cutoff | #8 |
| funding daiichi | #8 |
| nafronyl | #8 |
| chemotherapy low risk | #8 |
| structured algorithm | #8 |
| dimer concentration | #8 |
| 97 95 | #8 |
| patients excluded | #8 |
| ufh initial treatment | #8 |
| cancer pulmonary embolism | #8 |
| analysis apixaban | #8 |
| inr values patients | #8 |
| risk employees | #8 |
| comorbidity polypharmacy | #8 |
| acute symptomatic vte | #8 |
| xii deficient | #8 |
| prospective management | #8 |
| p0001 hasbled score | #8 |
| anticoagulation unprovoked vte | #8 |
| vitamin antagonists vkas | #8 |
| levonorgestrelcontaining | #8 |
| risks dvt | #8 |
| vka lmwh | #8 |
| occult cancer patients | #8 |
| aged phlebography | #8 |
| normal computed | #8 |
| products humans | #8 |
| 0·2 | #8 |
| recurrent vte bleeding | #8 |
| v617f jak2 | #8 |
| warfarin hazard ratio | #8 |
| proximal deepvein thrombosis | #8 |
| duration treatment | #8 |
| homocysteine markers | #8 |
| carriers fvl | #8 |
| apixaban enoxaparin | #8 |
| inr determination | #8 |
| vascular endothelial barrier | #8 |
| incidental pulmonary | #9 |
| thrombosis compared | #9 |
| months efficacy | #9 |
| therapeutic dose patients | #9 |
| factors thrombophlebitis | #9 |
| embolism venous | #9 |
| bled bleeding | #9 |
| thromboembolism cancer | #9 |
| carriers factor leiden | #9 |
| male oligosaccharides | #9 |
| cancer factor | #9 |
| ultrasonogram | #9 |
| nonpermanent | #9 |
| weight heparin | #9 |
| abnormal vaginal | #9 |
| oral antithrombins | #9 |
| cofact | #9 |
| independent committee | #9 |
| postdilution | #9 |
| major bleeding treatment | #9 |
| generation pill | #9 |
| iii concentrate | #9 |
| crcl 60 | #9 |
| characteristics severity | #9 |
| compression stockings prevention | #9 |
| cancer cell extravasation | #9 |
| büller | #9 |
| vte relatives | #9 |
| strategies dimer | #9 |
| enoxaparin factor | #9 |
| patients active cancer | #9 |
| combination stroke | #9 |
| placebo plasma levels | #9 |
| method enoxaparin | #9 |
| hemorr2hages atria | #9 |
| diagnosis mdct | #9 |
| normal ddimer | #9 |
| patients fxa inhibitors | #9 |
| discontinuing anticoagulation | #9 |
| lmwh mortality | #9 |
| acute medical illnesses | #9 |
| concomitant cancer | #9 |
| thrombosis venous thromboembolism | #9 |
| longterm treatment vte | #9 |
| daiichisankyo | #9 |
| oral contraceptive pregnancy | #9 |
| fxa inhibitor | #9 |
| serotonin platelet | #9 |
| treatment prophylaxis | #9 |
| fondaparinux cancer patients | #9 |
| tafi levels | #9 |
| vte rcts | #9 |
| homocysteine women | #9 |
| thrombosis thromboinflammation | #9 |
| atiii concentrates | #9 |
| comorbidities polypharmacy | #9 |
| lipoproteina women | #9 |
| cancer episode | #9 |
| heparin therapy patients | #9 |
| apixaban oral factor | #9 |
| prothrombin 20210a | #9 |
| edoxaban major bleeding | #9 |
| diagnostic prediction model | #9 |
| anticoagulant pathways | #9 |
| incidence postthrombotic syndrome | #9 |
| treatment edoxaban | #9 |
| embolism patients | #10 |
| rabbits administration | #10 |
| intimamedia thickness imt | #10 |
| thr incidence | #10 |
| patients endotoxemia | #10 |
| protein dic | #10 |
| crp test | #10 |
| oral thrombin inhibitor | #10 |
| treatment uedvt | #10 |
| 100 years discontinuation | #10 |
| leg veins | #10 |
| anticoagulants | #10 |
| cvd fh patients | #10 |
| cus diagnosis | #10 |
| schedule heparin | #10 |
| ageadjusted cutoff | #10 |
| cancer patients lmwh | #10 |
| thrombophlebitis adult | #10 |
| deficiencies antithrombin | #10 |
| patients venous thrombosis | #10 |
| 1215 patients | #10 |
| incidence major bleeding | #10 |
| treatment vitamin | #10 |
| oral administration dabigatran | #10 |
| ddimer concentration | #10 |
| magellan trial | #10 |
| factor levels patients | #10 |
| inherited thrombophilic factors | #10 |
| inr cases | #10 |
| aged antithrombin | #10 |
| asymptomatic pulmonary embolism | #10 |
| induced coagulation | #10 |
| fondaparinux risk | #10 |
| magellan study | #10 |
| venous thrombosis | #10 |
| incidence 1000 personyears | #10 |
| injection avidin | #10 |
| fii mutation | #10 |
| bled scores | #10 |
| extremity deep | #10 |
| vnv | #10 |
| rates recurrent vte | #10 |
| gramnegative septicemia | #10 |
| treatment aprotinin | #10 |
| embolism clinical | #10 |
| vte efficacy | #10 |
| dvt lower extremity | #10 |
| major bleeding crnmb | #10 |
| heparin nomogram | #10 |
| animal heparin | #10 |
| retrospective study efficacy | #10 |
| normohomocysteinemic | #10 |
| wells | #10 |
| rfviia blood loss | #10 |
| venous thromboembolic event | #10 |
| probability pulmonary embolism | #10 |
| hypocoagulable state | #10 |
| 4470 | #10 |
| nadroparine | #10 |
| single loss | #10 |
| snp scores | #10 |
| year years | #10 |
| subcutaneous metaanalysis | #10 |
| simplified geneva | #10 |
| factor prevention | #10 |
| pregnancy carriers | #10 |
| 598 patients | #10 |
| lmwh studies | #10 |
| thrombosis background | #10 |
| severity clinical | #10 |
| cancer patients vte | #10 |
| vte vwf | #11 |
| gentamicin treatment patients | #11 |
| factor venous | #11 |
| patients probability | #11 |
| patients cancer vte | #11 |
| cancer patients evidence | #11 |
| haemophilia vwd | #11 |
| edoxaban | #11 |
| screening cancer | #11 |
| 750 μg | #11 |
| previous venous | #11 |
| cancer patients dvt | #11 |
| pulmonary angiography venography | #11 |
| lmwh pregnancies | #11 |
| fondaparinux hemorrhage | #11 |
| pyridines thiazoles | #11 |
| d‐dimer levels | #11 |
| endotoxin assay | #11 |
| 30 microg ethinylestradiol | #11 |
| incidence major | #11 |
| reference testing | #11 |
| recombinant human tnf | #11 |
| sulfates dermatan | #11 |
| patients anticoagulant treatment | #11 |
| embolism recurrence | #11 |
| oral dabigatran | #11 |
| clinical pretest | #11 |
| adult anticoagulants | #11 |
| hospital lmwh | #11 |
| intensity anticoagulation | #11 |
| combination dimer | #11 |
| 880 patients | #11 |
| dvt | #11 |
| medical conferences | #11 |
| weight humans | #11 |
| air travel | #11 |
| embolism prevalence | #11 |
| knee clinical trials | #11 |
| mutations prevalence | #11 |
| pcc dabigatran | #11 |
| lmwh pregnancy | #11 |
| gps training | #11 |
| pulmonary embolism incidence | #11 |
| heparinoid org | #11 |
| carriers factor | #11 |
| variation inr | #11 |
| ufh studies | #11 |
| inhibitors hemorrhage | #11 |
| dabigatran enoxaparin | #11 |
| thromboembolism major | #11 |
| levels prolactin | #11 |
| org 10172 | #11 |
| endotoxin pentoxifylline | #11 |
| crnmb 95 | #11 |
| patients cvcs | #11 |
| pregnancyrelated complications | #11 |
| ldfr | #11 |
| livebirth rate | #12 |
| observation risk | #12 |
| treatment crt | #12 |
| bnp cardiac troponin | #12 |
| outpatient management patients | #12 |
| event recurrence | #12 |
| perelated | #12 |
| safety efficiency | #12 |
| 9702 | #12 |
| anticoagulation unprovoked | #12 |
| fondaparinux unfractionated heparin | #12 |
| warfarin recurrent vte | #12 |
| geneva score | #12 |
| dvt treatment | #12 |
| recurrent vte anticoagulation | #12 |
| recurrent vte | #12 |
| prevention venous thrombosis | #12 |
| control metaanalysis | #12 |
| female heparin humans | #12 |
| humanized arthroplasty | #12 |
| thrombosis dvt | #12 |
| patients incidental | #12 |
| 9295 | #12 |
| outcomes venous thromboembolism | #12 |
| ageadjusted ddimer | #12 |
| annual incidence vte | #12 |
| hirulog1 | #12 |
| 72 children | #12 |
| topic venous | #12 |
| pioped study | #12 |
| patients lmwhs | #12 |
| proximal veins | #12 |
| risk venous | #12 |
| warfarin treated | #12 |
| doseadjustment | #12 |
| patients lupus anticoagulant | #12 |
| bayer schering pharma | #12 |
| deficient women | #12 |
| factor leiden prothrombin | #12 |
| proximal vein | #12 |
| warfarin therapy inr | #12 |
| subsegmental pulmonary emboli | #12 |
| thrombin generation fibrinolysis | #12 |
| thrombophilic | #12 |
| stopping anticoagulation | #12 |
| hemodynamically stable | #12 |
| vka noacs | #12 |
| months primary | #12 |
| nephro | #12 |
| venous thromboembolism incidence | #12 |
| women factor | #12 |
| anticoagulant factor | #12 |
| noacs vka | #12 |
| paulin | #12 |
| crd42013003526 | #12 |
| vte recurrence risk | #12 |
| concomitant disorders | #12 |
| peghirudin | #12 |
| dimer testing | #13 |
| 86 percent | #13 |
| vte female humans | #13 |
| vte recurrence 95 | #13 |
| selective testing | #13 |
| bleeding events edoxaban | #13 |
| dabigatran 220 | #13 |
| treatment venous thromboembolism | #13 |
| dabigatran vte | #13 |
| safety doacs | #13 |
| rivaroxaban thiophenes | #13 |
| pselectin patients | #13 |
| 95 carriers | #13 |
| hematologic pregnancy trimester | #13 |
| daily subcutaneous | #13 |
| time prothrombin | #13 |
| superficial thrombophlebitis | #13 |
| levels factor | #13 |
| marder score | #13 |
| factor leiden mutation | #13 |
| antithrombin iii activity | #13 |
| heparin low | #13 |
| uedvt | #13 |
| conventional anticoagulants | #13 |
| factor viii apc | #13 |
| dvt lower | #13 |
| strain gauge plethysmography | #13 |
| vte major | #13 |
| patients thrombophilia | #13 |
| spiral computed tomography | #13 |
| plethysmography | #13 |
| vte | #13 |
| bayer healthcare | #13 |
| vte 64 | #13 |
| category studies | #13 |
| groups inr | #13 |
| occult cancer | #13 |
| concomitant antiplatelet therapy | #13 |
| thrombosis acute | #13 |
| plethysmograms | #13 |
| arterial thromboembolism ate | #13 |
| arixtra | #13 |
| safety oral | #13 |
| prevention venous thromboembolism | #13 |
| vte groups | #13 |
| nct00986154 | #13 |
| obesity haemophilia patients | #13 |
| indication anticoagulation | #13 |
| patients anticoagulant | #13 |
| association venous thrombosis | #13 |
| dimer threshold | #13 |
| inhibition tnf | #13 |
| continuous intravenous heparin | #13 |
| thrombosis young | #13 |
| major hip | #13 |
| inferiority efficacy | #13 |
| ufh dalteparin | #13 |
| deepvein thrombosis dvt | #13 |
| clinical decision rules | #13 |
| randomized cross | #13 |
| recombinant hirudin rhirudin | #13 |
| placebo rfviia | #14 |
| crnm | #14 |
| thrombophilia patients | #14 |
| aged plethysmography | #14 |
| experimental endotoxaemia | #14 |
| atiii deficiency | #14 |
| effects hyperthyroidism | #14 |
| incidence severe pph | #14 |
| pregnancy venous | #14 |
| higher ddimer levels | #14 |
| vte statin | #14 |
| recurrent venous | #14 |
| plasminogen apoa | #14 |
| fvl carriers | #14 |
| safety edoxaban | #14 |
| treatment duration patients | #14 |
| conventionaltherapy | #14 |
| cadherins endothelium | #14 |
| aspirin women | #14 |
| gastrointestinal bleeding patients | #14 |
| costs dvt | #14 |
| ultrasound strategies | #14 |
| lmwh vka | #14 |
| awareness pad | #14 |
| cancer patients anticoagulation | #14 |
| vte months | #14 |
| patients dvt | #14 |
| acute deep | #14 |
| patients vka therapy | #14 |
| thromboembolism age | #14 |
| symptomatic pulmonary | #14 |
| unprovoked vte vte | #14 |
| obstetric complications women | #14 |
| treated lmwh | #14 |
| anticoagulant rivaroxaban | #14 |
| revised geneva | #14 |
| limited screening | #14 |
| edoxaban warfarin | #14 |
| aged anticoagulants | #14 |
| loss women | #14 |
| patients outpatients | #14 |
| riete score | #14 |
| standard heparin | #14 |
| 17 placebo | #14 |
| 12 kg1 | #14 |
| thrombosis | #14 |
| recurrent venous thromboembolism | #14 |
| female fibrin | #14 |
| patients acute vte | #14 |
| edoxaban oral factor | #14 |
| low molecular | #14 |
| factor viii levels | #14 |
| dvt lower extremities | #14 |
| bolus intravenous injection | #14 |
| doseranging study | #14 |
| thrombosis diagnosis | #15 |
| abdominal pelvic | #15 |
| patients ctpa | #15 |
| probability assessment | #15 |
| established vte | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| generation oral | #15 |
| control subjects prevalence | #15 |
| symptomatic events | #15 |
| edoxaban treatment | #15 |
| subcutaneous regimen | #15 |
| 500 pg | #15 |
| arg506 | #15 |
| vitaminkantagonists | #15 |
| subcutaneous enoxaparin | #15 |
| antagonist vka | #15 |
| fondaparinux efficacy | #15 |
| experimental thrombosis | #15 |
| studies pulmonary | #15 |
| patients vitamin antagonists | #15 |
| cardiovascular diseases thrombosis | #15 |
| recombinant factor viia | #15 |
| thyroid hormone excess | #15 |
| lomoparan | #15 |
| cteph incidence | #15 |
| inr range | #15 |
| coc vte | #15 |
| pregnancy outcome pregnancy | #15 |
| clinically relevant endpoints | #15 |
| primary safety outcome | #15 |
| inr patient | #15 |
| enoxaparin vte | #15 |
| coagulation | #15 |
| diagnosis venous | #15 |
| treatment 12 months | #15 |
| factor leiden | #15 |
| oral direct factor | #15 |
| anticoagulants patients | #15 |
| prior venous thromboembolism | #15 |
| arg562 | #15 |
| activation contact | #15 |
| doacs aspirin | #15 |
| lmwh ufh | #15 |
| thrombus growth | #15 |
| prophylaxis venous thromboembolism | #15 |
| khorana score | #15 |
| thrombinography | #15 |
| 6 months placebo | #16 |
| test clinical | #16 |
| 100 95 | #16 |
| bleeding aged | #16 |
| positivity threshold | #16 |
| major bleeding anticoagulation | #16 |
| ddimer levels patients | #16 |
| factor inhibitor | #16 |
| vterelated death | #16 |
| abdomino | #16 |
| vte khorana score | #16 |
| deep venous thrombosis | #16 |
| warfarin acenocoumarol | #16 |
| arterial vascular events | #16 |
| thrombosis low | #16 |
| cancer screening patients | #16 |
| combination clinical | #16 |
| thromboembolism time | #16 |
| thrombosis adult | #16 |
| viia activity | #16 |
| cancer cancer patients | #16 |
| risk clinically | #16 |
| factors major | #16 |
| recurrent symptomatic | #16 |
| postthrombotic syndrome children | #16 |
| analysis rivaroxaban | #16 |
| venous thrombosis warfarin | #16 |
| avws patients | #16 |
| netilmicin gentamicin | #16 |
| impaired fibrinolysis | #16 |
| occult cancer detection | #16 |
| women unexplained | #16 |
| thrombosis haemostasis | #16 |
| patients acenocoumarol | #16 |
| major bleeding events | #16 |
| dvt lmwh | #16 |
| subsequent pregnancy loss | #16 |
| thrombosis association | #16 |
| factor monoclonal | #17 |
| management crt | #17 |
| thromboembolism patients | #17 |
| anticoagulants clinical | #17 |
| ctscans | #17 |
| mutation women | #17 |
| 516 patients | #17 |
| patients overt hypothyroidism | #17 |
| prohemostatic | #17 |
| female humans vte | #17 |
| vte edoxaban | #17 |
| incidence pts | #17 |
| diagnosis svt | #17 |
| recurrent vte events | #17 |
| lmwhs patients | #17 |
| compared enoxaparin | #17 |
| gentamicin netilmicin | #17 |
| endotoxemia bacteremia | #17 |
| hematoma heparin | #17 |
| factors venous | #17 |
| 2688 | #17 |
| dimer assay | #17 |
| scan classification | #17 |
| anticoagulant therapy patients | #17 |
| patients impedance | #17 |
| lower specificity | #17 |
| 12 months patients | #17 |
| fibrinolysis treatment | #17 |
| topic hemorrhage humans | #17 |
| thrombosis clinical | #17 |
| fragment f1 | #17 |
| rivaroxaban oral factor | #17 |
| vkorc1 gene | #17 |
| women mutation | #17 |
| pharmo record linkage | #17 |
| dvt prevention | #17 |
| excessive blood loss | #17 |
| permanent patients | #17 |
| anticoagulants drug | #17 |
| aptt heparin | #18 |
| women pregnancy loss | #18 |
| 023 | #18 |
| venous thromboembolism rivaroxaban | #18 |
| poc test | #18 |
| 4 clinical | #18 |
| simplired | #18 |
| stable anticoagulation | #18 |
| vka edoxaban | #18 |
| apc thrombin generation | #18 |
| cancer vte | #18 |
| combined form | #18 |
| flight hours | #18 |
| commercial airline pilots | #18 |
| hivinfected patients cart | #18 |
| proximal vein thrombosis | #18 |
| weight adjusted | #18 |
| outcome events | #18 |
| treatment vkas | #18 |
| thromboembolism venous | #18 |
| prothrombin g20210a | #18 |
| annual incidence | #18 |
| vka vte | #18 |
| warfarin hazard | #18 |
| relevant nonmajor | #18 |
| intravenous heparin therapy | #18 |
| favor lmwh | #18 |
| antithrombotic treatment patients | #18 |
| thrombosis total | #18 |
| lmwh doacs | #18 |
| patients strategy | #18 |
| edoxaban vte | #18 |
| diagnostic strategy | #18 |
| sanofi aventis | #18 |
| thrombosis pulmonary | #18 |
| symptomatic dvt | #19 |
| fondaparinux enoxaparin | #19 |
| patients elevated biomarkers | #19 |
| 56 95 | #19 |
| antibodynegative | #19 |
| dvt rivaroxaban | #19 |
| edoxaban dose | #19 |
| retropubic prostatectomy | #19 |
| low platelets | #19 |
| local angiogenesis | #19 |
| ddimer tests | #19 |
| ipdma | #19 |
| adjusted dose | #19 |
| fibrinolytic response | #19 |
| recurrent venous thrombosis | #19 |
| endogenous fibrinolysis | #19 |
| systemic activation coagulation | #19 |
| acute recurrent | #19 |
| increased fibrinolytic activity | #19 |
| treatment heparin | #19 |
| increased risk relatives | #19 |
| coagulation studies | #19 |
| prognostic echocardiography | #19 |
| venography sensitivity | #19 |
| active search | #19 |
| extended oral | #19 |
| vwf vte | #19 |
| oral dabigatran enoxaparin | #19 |
| venous thromboembolism relatives | #19 |
| 35 women | #19 |
| patients prevalence | #19 |
| vitamin antagonist | #19 |
| recurrence vte | #19 |
| abnormal ultrasound | #19 |
| ufh lmwh | #19 |
| subcutaneous dalteparin | #19 |
| lmwh patients | #19 |
| patients derivation | #19 |
| patients sspe | #19 |
| patients major bleeding | #19 |
| versions version | #19 |
| thromboembolism administration | #19 |
| objective testing | #19 |
| doubleblinding | #19 |
| studies factor | #19 |
| blindly | #20 |
| incidences death | #20 |
| excluded patients | #20 |
| synthetic cross | #20 |
| cancer severity | #20 |
| single criterion | #20 |
| warfarin edoxaban | #20 |
| residual venous | #20 |
| absolute risk | #20 |
| therapy rivaroxaban | #20 |
| anticoagulation clinic | #20 |
| distance treatment | #20 |
| shr 95 | #20 |
| abi measurement | #20 |
| treatment vte | #20 |
| new agent | #20 |
| subsegmental | #20 |
| ctnt bnp | #20 |
| proteins thrombin | #20 |
| malignancy time | #20 |
| guidance ssc | #20 |
| prothrombin mutation | #20 |
| nadroparin | #20 |
| patients ddimer testing | #20 |
| standardtherapy hazard ratio | #20 |
| symptomatic venous thrombosis | #20 |
| intravenous injections | #20 |
| thrombophilia vte | #20 |
| versions questionnaire | #20 |
| recurrence bleeding | #20 |
| thrombosis ultrasonography | #20 |
| established atherosclerosis | #20 |
| risk thrombophilia | #20 |
| antagonists vkas | #20 |
| statin vte | #20 |
| calf veins | #20 |
| life venous thrombosis | #20 |
| portola | #20 |
| diagnostic workup patients | #20 |
| antitpo | #20 |
| impedance plethysmography ipg | #20 |
| abi risk factors | #20 |
| control situation | #20 |
| compared ufh | #20 |
| pregnancyrelated vte | #20 |
| injections subcutaneous | #20 |
| carriers prothrombin | #20 |
| dabigatran 150 | #20 |
| risk cohort study | #21 |
| carriers noncarriers | #21 |
| thrombosis anticoagulants | #21 |
| fibrinolysis inflammation | #21 |
| prothrombin 20210 | #21 |
| occult malignancy | #21 |
| hemostatic abnormalities | #21 |
| concomitant anti | #21 |
| treatment acenocoumarol | #21 |
| venogram | #21 |
| distance quality | #21 |
| treatment apixaban | #21 |
| ddimer concentrations | #21 |
| major bleeding patients | #21 |
| current standard treatment | #21 |
| internists cardiologists | #21 |
| thromb | #21 |
| doacs lmwhs | #21 |
| d‐dimer | #21 |
| deep venous | #21 |
| patients 3 months | #21 |
| discriminatory performance | #21 |
| vte patients | #21 |
| outcome incidence | #21 |
| hemodynamically stable patients | #21 |
| disease ischemic | #21 |
| treatment dvt | #22 |
| dichotomously | #22 |
| cmax ctrough | #22 |
| bleeding treatment | #22 |
| cttr | #22 |
| ttr inr | #22 |
| vascular endotoxins | #22 |
| daily enoxaparin | #22 |
| alternative anticoagulation | #22 |
| dose subcutaneous | #22 |
| acute vte | #22 |
| patients immobilization | #22 |
| dimer age | #22 |
| patients recurrent symptoms | #22 |
| venous thromboembolic | #22 |
| riskbenefit ratio | #22 |
| safety treatment | #22 |
| patients severe hf | #22 |
| lpa plasminogen | #22 |
| doppler venous thrombosis | #22 |
| host defense response | #22 |
| recurrent thromboembolism | #22 |
| hormonal cross | #22 |
| anticoagulants humans | #22 |
| public awareness | #22 |
| time inr | #22 |
| thrombophilia screening | #22 |
| anticoagulants heparin | #22 |
| patientyears | #22 |
| n1157 | #23 |
| elevated ctni | #23 |
| ambulatory cancer patients | #23 |
| direct factor inhibitors | #23 |
| hasbled score | #23 |
| clotbound thrombin | #23 |
| prevalence venous thromboembolism | #23 |
| vte studies | #23 |
| percentage increase | #23 |
| thromboembolism anticoagulants | #23 |
| life pulmonary embolism | #23 |
| fondaparinux | #23 |
| recurrence venous | #23 |
| patients coagulation disorders | #23 |
| bidirectional relation | #23 |
| development dic | #23 |
| rivaroxaban dosing | #23 |
| cancer patients risk | #23 |
| kakkar | #23 |
| 011 | #23 |
| odis | #23 |
| 2 investigators | #23 |
| normal angiogram | #23 |
| venous arterial thrombosis | #23 |
| time platelet | #23 |
| lower extremity amputation | #23 |
| 5392 | #23 |
| gentamicin patients | #23 |
| enoxaparin 40 | #23 |
| standardduration | #23 |
| bleeding complication | #24 |
| fondaparinux placebo | #24 |
| presence dvt | #24 |
| specific antidote | #24 |
| parameters fibrinolysis | #24 |
| levels fviii | #24 |
| therapy heparin | #24 |
| patients acute treatment | #24 |
| viiic | #24 |
| a21gly | #24 |
| patients severe bleeding | #24 |
| 049 | #24 |
| rates venous thromboembolism | #24 |
| thrombosis carriers | #24 |
| independent external validation | #24 |
| followup incidence | #24 |
| food drugs | #24 |
| years episode | #24 |
| ddimer testing | #24 |
| month incidence | #24 |
| lowmolecularweight humans | #24 |
| predefined criteria | #24 |
| subtherapeutic | #24 |
| overt hyperthyroidism | #24 |
| ufh patients | #24 |
| prevalence deficiencies | #24 |
| desogestrel levonorgestrel | #24 |
| recurrent thromboembolism patients | #24 |
| safety fondaparinux | #24 |
| patients abnormal perfusion | #24 |
| recurrent pulmonary embolism | #24 |
| lmwh treatment | #25 |
| fibrinogen degradation | #25 |
| suggestions improvement | #25 |
| anatomical extent | #25 |
| studies lmwh | #25 |
| patients gastrointestinal bleeding | #25 |
| cha2ds2vasc chads2 | #25 |
| willebrand factor adamts13 | #25 |
| expert radiologists | #25 |
| middeldorp | #25 |
| xii activity | #25 |
| vte clinical | #25 |
| factors anticoagulants | #25 |
| specificity efficiency | #25 |
| influence smoking | #25 |
| fatima | #25 |
| thromboembolism acute | #25 |
| f1 2 levels | #25 |
| amadeus | #25 |
| sepsis intravascular coagulation | #25 |
| perfusion lung scan | #25 |
| treatment symptomatic | #25 |
| rethoracotomy | #26 |
| dalteparin ufh | #26 |
| edoxaban vka | #26 |
| patients essential thrombocythaemia | #26 |
| edoxaban versus | #26 |
| miscarriage stillbirth | #26 |
| venous thromboemboli | #26 |
| hormonal manipulation | #26 |
| major bleeding bleeding | #26 |
| doacs vitamin antagonists | #26 |
| homozygous carriers | #26 |
| rate recurrent vte | #26 |
| unprovoked vte | #26 |
| 9715 | #26 |
| failure rate | #26 |
| events year | #26 |
| viia complex | #26 |
| parameters risk | #26 |
| ecq | #26 |
| patients cdr | #26 |
| asymptomatic carriers | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| patients symptomatic dvt | #26 |
| treatment lmwh | #26 |
| specificity negative predictive | #26 |
| extremity venous | #27 |
| cancer spread | #27 |
| patients elevated levels | #27 |
| anticoagulants blood | #27 |
| thrombocytopenia antibodies | #27 |
| vte thr | #27 |
| 0·63 | #27 |
| patients 50 | #27 |
| airline pilots | #27 |
| training gps | #27 |
| patients major hemorrhage | #27 |
| current guidance | #27 |
| enoxaparin female | #27 |
| day 35 | #27 |
| perfusion lung | #27 |
| lowmolecularweight heparin patients | #27 |
| thrombosis venous | #27 |
| thrombophlebitis | #27 |
| combined training | #27 |
| female heterozygote | #27 |
| nonmajor | #27 |
| noncarriers 95 | #27 |
| vte doacs | #27 |
| months studies | #27 |
| anticoagulants factor | #27 |
| venous thromboembolism carriers | #27 |
| unprovoked venous | #27 |
| lmwh prophylaxis | #27 |
| low molecularweight heparin | #27 |
| treating physician | #27 |
| npv patients | #27 |
| unexplained | #28 |
| objective tests | #28 |
| coagulation tissue factor | #28 |
| monitoring therapy | #28 |
| receiving rivaroxaban | #28 |
| pembqol | #28 |
| cancer venous thromboembolism | #28 |
| tests diagnostic | #28 |
| vte 6 months | #28 |
| presentation followup | #28 |
| anticoagulants compared | #28 |
| embolism retrospective | #28 |
| rfviia placebo | #28 |
| specific reversal agent | #28 |
| factors recurrent | #28 |
| patients unprovoked | #28 |
| vitamin aged | #28 |
| anticoagulation women | #28 |
| acutely medical patients | #28 |
| 4650 | #28 |
| hirudin therapy | #28 |
| 2½ | #28 |
| apc plasma | #28 |
| pph severe pph | #28 |
| therapeutic doses | #28 |
| years year | #29 |
| recurrence svt | #29 |
| oral glucocorticoids | #29 |
| dvt pulmonary embolism | #29 |
| pulmonary embolism recurrence | #29 |
| blind trials | #29 |
| acenocoumarol patients | #29 |
| aged morpholines | #29 |
| current management strategies | #29 |
| direct oral anticoagulants | #29 |
| pulmonary angiography | #29 |
| prediction scores | #29 |
| thrombo | #29 |
| pulmonary embolism death | #29 |
| major bleeding rivaroxaban | #29 |
| g20210a mutation | #29 |
| heparin versus | #29 |
| sex‐specific differences | #29 |
| cindexes | #29 |
| 8240 | #29 |
| thrombosis treatment | #29 |
| 1000 individuals | #29 |
| dabigatran pcc | #29 |
| plateletactivating antibodies | #29 |
| authors incidence | #29 |
| spread cancer | #29 |
| bleeding increased | #29 |
| pbac score | #29 |
| thrombosis 95 | #29 |
| aspirin placebo | #29 |
| diagnosis dvt | #29 |
| patients standard therapy | #29 |
| patients avws | #29 |
| resistance activated protein | #29 |
| dutch famine | #29 |
| aminoglycoside therapy | #29 |
| septicemia | #29 |
| subcutaneous heparin | #30 |
| direct oral factor | #30 |
| vte coc | #30 |
| residual thrombosis | #30 |
| ufh vte | #30 |
| 95 risk | #30 |
| rule patients | #30 |
| support techniques | #30 |
| new anticoagulants | #30 |
| thromboembolism warfarin | #30 |
| prevention venous | #30 |
| cancer venous | #30 |
| administration pentoxifylline | #30 |
| patients vte | #30 |
| embolism risk | #30 |
| xii factor | #30 |
| f1 2 | #30 |
| markers coagulation activation | #30 |
| 1000 personyears incidence | #30 |
| costs diagnosis | #30 |
| doac vka | #30 |
| rfviia novoseven | #31 |
| recurrent episode | #31 |
| women recurrent miscarriage | #31 |
| bled | #31 |
| placebo observation | #31 |
| vte ufh | #31 |
| pharmacological prophylaxis | #31 |
| term risk | #31 |
| thromboembolism adolescent | #31 |
| events 95 | #31 |
| 8755 | #31 |
| recurrent patients | #31 |
| standardtherapy | #31 |
| iii activity | #31 |
| antithrombotic therapies | #31 |
| patients deepvein thrombosis | #31 |
| rhir | #31 |
| 2 antiplasmin | #31 |
| incidence cteph | #31 |
| analysis reviewers | #31 |
| dvt pulmonary | #31 |
| incidence pph | #31 |
| activation blood coagulation | #31 |
| imaging sensitivity specificity | #31 |
| inhibitor edoxaban | #31 |
| recurrent vte patients | #31 |
| extended prophylaxis | #31 |
| experimental endotoxemia | #31 |
| prevalence probability | #31 |
| dimer cutoff | #31 |
| apixaban placebo | #31 |
| ventilation scintigraphy | #31 |
| thromboprophylaxis risk | #31 |
| 0206 | #31 |
| ufh fondaparinux | #31 |
| leiden mutation | #32 |
| low clinical | #32 |
| year 95 | #32 |
| ufh | #32 |
| parenteral anticoagulation | #32 |
| suspected patients | #32 |
| treatment anticoagulants | #32 |
| negative dimer | #32 |
| generation patients | #32 |
| netherlands predictive | #32 |
| international society thrombosis | #32 |
| factors thrombolytic | #32 |
| age adjusted | #32 |
| khorana score patients | #32 |
| resistance activated | #32 |
| factor female | #32 |
| negative septicemia | #32 |
| parenteral anticoagulants | #32 |
| warfarin vte | #32 |
| normal genotype | #32 |
| varicosis | #32 |
| warfarin risks | #33 |
| subcutaneous male | #33 |
| heparin lmwh | #33 |
| chapter patients | #33 |
| rhirudin | #33 |
| active implementation | #33 |
| nephrotoxicity gentamicin | #33 |
| apixaban treatment | #33 |
| low probability | #33 |
| pulmonary angiogram | #33 |
| anticoagulant protein | #33 |
| additional tests | #33 |
| prophylaxis vte | #33 |
| data meta | #33 |
| mega study | #33 |
| cancer patients diagnosis | #33 |
| factor viii patients | #33 |
| activation factors | #33 |
| unitage | #33 |
| thromboembolism young | #33 |
| pregnancy loss women | #34 |
| 9241 | #34 |
| plasmin alpha | #34 |
| control trials | #34 |
| subsegmental pulmonary embolism | #34 |
| phytonadione | #34 |
| 590 | #34 |
| warfarin adult | #34 |
| bilateral venography | #34 |
| deficiency protein | #34 |
| vte thrombophilia | #34 |
| anticoagulant | #34 |
| 3 months treatment | #34 |
| grade 1a | #34 |
| apcsr | #34 |
| 10 95 | #34 |
| compare efficacy | #34 |
| hemorrhage heparin humans | #34 |
| lmwh unfractionated heparin | #34 |
| vte compared | #34 |
| reocclusion patients | #34 |
| thrombosis lower | #34 |
| 36 95 | #35 |
| statin association | #35 |
| weekly subcutaneous | #35 |
| risk members | #35 |
| enoxaparin prevention | #35 |
| prevention model | #35 |
| rviia | #35 |
| radiologists diagnosis | #35 |
| pph blood loss | #35 |
| anticoagulants benzimidazoles | #35 |
| neoplasms venous | #35 |
| lung scanning | #35 |
| surgery hip | #35 |
| activation coagulation | #35 |
| embolism | #35 |
| patients efficiency | #35 |
| viii levels | #36 |
| peripheral endovascular | #36 |
| factors travel | #36 |
| venous thromboembolic disease | #36 |
| 4139 | #36 |
| venous thromboembolism dabigatran | #36 |
| treatment acute vte | #36 |
| 287 patients | #36 |
| iii antithrombin | #36 |
| 1698 | #36 |
| catheterrelated infection | #36 |
| hellp patients | #36 |
| thrombophilia venous | #36 |
| regular monitoring | #36 |
| acute symptomatic | #36 |
| levels coagulation | #36 |
| novoseven | #36 |
| inherited risk factors | #36 |
| riskbenefit | #36 |
| dose reduction patients | #36 |
| fibrinolytic activation | #36 |
| fibrinogen depletion | #36 |
| studies echocardiography | #36 |
| factors thrombophilia | #37 |
| ctpa patients | #37 |
| perelated mortality | #37 |
| vte increased | #37 |
| ototoxicity nephrotoxicity | #37 |
| magellan | #37 |
| screening occult | #37 |
| risk venous thrombosis | #37 |
| outcome composite | #37 |
| prophylactic heparin | #37 |
| genotype 95 | #37 |
| anticoagulants prevention | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| suspected venous | #37 |
| bagsvaerd | #37 |
| recombinant hirudin | #37 |
| cumulative incidence vte | #37 |
| anticoagulant action | #37 |
| warfarin 95 | #37 |
| excluding | #37 |
| tat complexes | #37 |
| risk factors pts | #37 |
| venography | #37 |
| pad studies | #37 |
| thrombosis humans | #37 |
| lwmh | #37 |
| recurrence day | #38 |
| congenital deficiencies | #38 |
| catheterrelated thrombosis | #38 |
| 3306 | #38 |
| anticoagulants female humans | #38 |
| fetal loss women | #38 |
| patients ddimer levels | #38 |
| sensitivity biomarkers | #38 |
| rivaroxaban placebo | #38 |
| vte cancer patients | #38 |
| doac lmwh | #38 |
| submassive pulmonary | #38 |
| vte bleeding | #38 |
| 10 total | #38 |
| age recurrence | #38 |
| restenosis reocclusion | #38 |
| 2835 | #38 |
| nonmajor bleeding | #38 |
| coagulation protein | #38 |
| doacs | #39 |
| children familial hypercholesterolemia | #39 |
| septic syndrome | #39 |
| specificity patients | #39 |
| 277 patients | #39 |
| compression stocking | #39 |
| low molecular weight | #39 |
| time compression | #39 |
| superficial vein thrombosis | #39 |
| enoxaparin placebo | #39 |
| heparins lmwhs | #39 |
| systemic inflammatory responses | #39 |
| incidence patients | #39 |
| continued treatment | #39 |
| incidence cancer | #39 |
| submassive | #39 |
| subcutaneous intention | #39 |
| fibrin fibrinogen | #39 |
| diagnostic prediction | #39 |
| embolus | #39 |
| endotoxininduced | #40 |
| common femoral vein | #40 |
| patients normal | #40 |
| thrombinantithrombin complexes | #40 |
| clotting activation | #40 |
| day 6 months | #40 |
| dalteparin treatment | #40 |
| standardized definition | #40 |
| international clinical | #40 |
| anticoagulant therapy | #40 |
| fviiic | #40 |
| tfmp | #40 |
| activatable fibrinolysis | #40 |
| pemb | #40 |
| therapeutic dosages | #40 |
| ambulatory cancer | #40 |
| episode venous thromboembolism | #40 |
| anticoagulation therapy patients | #40 |
| arterial vascular | #40 |
| grade 1a patients | #40 |
| bleeding | #40 |
| risk recurrent vte | #41 |
| anticoagulated patients | #41 |
| endotoxin induced | #41 |
| 7268 | #41 |
| 95 genotype | #41 |
| heparin therapy | #41 |
| calf vein thrombosis | #41 |
| submassive pulmonary embolism | #41 |
| cancer lmwh | #41 |
| placebo 6 months | #41 |
| triage tests | #41 |
| pentasaccharides | #41 |
| dabigatran etexilate | #41 |
| lowmolecularweight heparins | #41 |
| lung scintigraphy | #41 |
| prophylaxis venous | #42 |
| 8101 | #42 |
| neoplasms thrombosis | #42 |
| anticoagulation risk | #42 |
| netilmicin | #42 |
| patients vasopressors | #42 |
| cell extravasation | #42 |
| patients silent | #42 |
| major contributor | #42 |
| patients prospective | #42 |
| standardization committee | #42 |
| type graft | #42 |
| stroke thrombosis | #42 |
| thrombosis administration | #42 |
| initial treatment | #43 |
| 543 patients | #43 |
| ischemic events | #43 |
| rtap | #43 |
| vkas patients | #43 |
| warfarin anticoagulants | #43 |
| venous thromboembolism vte | #43 |
| post‐thrombotic syndrome | #43 |
| probability patients | #43 |
| cancer adjusted | #43 |
| patients vte risk | #43 |
| fetal loss | #43 |
| heparin risk | #43 |
| monthly incidence | #43 |
| draft document | #43 |
| venous thrombosis thrombophilia | #43 |
| edoxaban therapy | #44 |
| recurrent vte 95 | #44 |
| uedvt patients | #44 |
| restoration euthyroidism | #44 |
| protein sepsis | #44 |
| role coagulation | #44 |
| 10–14 | #44 |
| experimental venous thrombosis | #44 |
| expert physicians | #44 |
| 95 pulmonary embolism | #44 |
| indications patients | #44 |
| efficiency models | #44 |
| factors thromboembolism | #44 |
| nonvka oral anticoagulants | #44 |
| mild hyperhomocysteinaemia | #44 |
| enoxaparin risk | #44 |
| 20 30 | #44 |
| rate venous | #44 |
| patients tinzaparin | #44 |
| wells score | #45 |
| patients bnp | #45 |
| coagulation activation | #45 |
| years algorithm | #45 |
| dose lmwh | #45 |
| dvt patients | #45 |
| treated warfarin | #45 |
| coumarin therapy | #45 |
| venous thrombotic | #45 |
| dose adjusted | #45 |
| fondaparinux patients | #45 |
| oral direct | #45 |
| 95 warfarin | #45 |
| revascularisation procedures | #45 |
| day levels | #46 |
| stroke risk assessment | #46 |
| abtpo | #46 |
| daily rivaroxaban | #46 |
| pioped | #46 |
| hospital outpatients | #46 |
| extended duration | #46 |
| patients unprovoked vte | #46 |
| ssc isth | #46 |
| percent confidence | #46 |
| prothrombin fragment f1 | #46 |
| major bleeding placebo | #46 |
| healthcare settings | #46 |
| treatment model | #46 |
| standard therapy | #46 |
| management venous | #46 |
| bleeding rivaroxaban | #46 |
| ruling | #46 |
| bristol myers squibb | #47 |
| new oral anticoagulant | #47 |
| outcome vitamin | #47 |
| ambulatory anticoagulants | #47 |
| mechanical prophylaxis | #47 |
| plasma ddimer levels | #47 |
| male methimazole | #47 |
| central venous lines | #47 |
| roccurve | #47 |
| iiia receptors | #47 |
| episode vte | #47 |
| boehringer ingelheim | #47 |
| mutation pregnancy | #47 |
| risk recurrent | #48 |
| daiichi | #48 |
| thrombotic burden | #48 |
| rivaroxaban compared | #48 |
| patients acute dvt | #48 |
| patients pulmonary | #48 |
| small studies | #48 |
| subcommittee | #48 |
| travel risk | #48 |
| thromboprophylactic | #48 |
| factors rivaroxaban | #48 |
| diagnosis physicians | #48 |
| fondaparinux heparin | #48 |
| intermediate risk risk | #48 |
| recurrence venous thromboembolism | #48 |
| elevated plasma levels | #48 |
| women aspirin | #49 |
| calf vein | #49 |
| rivaroxaban prevention | #49 |
| factor viii deficiency | #49 |
| levels protein | #49 |
| lowmolecularweight heparin lmwh | #49 |
| vte diagnosis | #49 |
| enoxaparin | #49 |
| dvt diagnosis | #50 |
| acute respiratory insufficiency | #50 |
| outpatient therapy | #50 |
| buller | #50 |
| vitamink antagonists | #50 |
| intensity treatment | #50 |
| treatment threshold | #50 |
| atria patients | #50 |
| incidence venous thromboembolism | #50 |
| prospective diagnostic | #50 |
| nonselective betablockers | #50 |
| etexilate | #50 |
| cardiac surgery mortality | #50 |
| transient risk factor | #50 |
| thromboembolism aged | #50 |
| acenocoumarol | #51 |
| effects coagulation | #51 |
| global disease | #51 |
| patients 11 | #51 |
| discrimination model | #51 |
| strategies treatment | #51 |
| tomography pulmonary | #51 |
| factor vte | #51 |
| 95 apixaban | #51 |
| previous survey | #51 |
| protein deficiencies | #51 |
| normal perfusion | #51 |
| lung scans | #52 |
| pdvt | #52 |
| 3 month | #52 |
| hematologic malignancies patients | #52 |
| unnecessarily | #52 |
| inhibitors heparin | #52 |
| doacs vka | #52 |
| lmwh fondaparinux | #52 |
| risk venous thromboembolism | #52 |
| patients comorbid conditions | #52 |
| apixaban vte | #52 |
| svt patients | #52 |
| 1·12 | #52 |
| free thyroxine ft4 | #52 |
| vte major bleeding | #52 |
| hemostatic balance | #53 |
| reported incidence | #53 |
| warfarintreated patients | #53 |
| cross study | #53 |
| 40 daily | #53 |
| 1522 | #53 |
| thrombophilic factors | #53 |
| postthrombotic syndrome | #53 |
| preference patients | #53 |
| 479 patients | #53 |
| thromboembolism prevention | #53 |
| suspected venous thromboembolism | #53 |
| absolute risks | #53 |
| versus enoxaparin | #53 |
| patients initially | #53 |
| patients obese | #54 |
| patients incidence | #54 |
| bled score | #54 |
| vte mortality | #54 |
| 378 patients | #54 |
| major bleeds | #54 |
| acquired risk factors | #54 |
| pai1 levels patients | #54 |
| 034 | #54 |
| antithrombotic drug | #54 |
| thromboembolism death | #54 |
| prethrombotic | #54 |
| 2537 | #54 |
| chads2 cha2ds2vasc | #54 |
| endocrine disorders | #54 |
| familial thrombophilia | #54 |
| male pulmonary embolism | #54 |
| biological pan | #55 |
| dosereduction | #55 |
| methods randomized | #55 |
| proximal extent | #55 |
| treatment thresholds | #55 |
| legs patients | #55 |
| anticoagulants arthroplasty replacement | #55 |
| nondeficient | #55 |
| long term risk | #55 |
| compared lmwh | #55 |
| unfractionated heparin | #55 |
| insurances | #55 |
| unfractionated heparin ufh | #55 |
| rivaroxaban | #55 |
| preeclampsia hellp syndrome | #56 |
| enoxaparin patients | #56 |
| physicians guidelines | #56 |
| venous outflow obstruction | #56 |
| level mortality | #56 |
| deficiency prevalence | #56 |
| risk major bleeding | #56 |
| vte death | #56 |
| vasopressors | #56 |
| inr values | #56 |
| reduced capacity | #56 |
| vitamin warfarin | #56 |
| time event | #56 |
| seventh accp conference | #56 |
| weight heparins | #56 |
| enoxaparin rivaroxaban | #56 |
| tromboembólica | #56 |
| 20210a | #56 |
| major bleeding apixaban | #56 |
| calf dvt | #57 |
| ctscan | #57 |
| antithrombin iii heparin | #57 |
| levels survival | #57 |
| inhibitors female humans | #57 |
| clinical models | #57 |
| subsegmental pulmonary | #57 |
| risk factors vte | #57 |
| doacs patients | #58 |
| inhibitors female | #58 |
| malignancy mortality | #58 |
| thrombin activatable | #58 |
| fibrinolysis humans | #58 |
| unfractionated heparin patients | #58 |
| pharmo | #58 |
| ruled | #58 |
| spiral computed | #58 |
| lowmolecular weight heparin | #58 |
| acute venous thromboembolism | #59 |
| risk periods | #59 |
| incidence symptomatic | #59 |
| safety warfarin | #59 |
| direct oral | #59 |
| risk factors sensitivity | #59 |
| clot lysis time | #59 |
| aventis | #59 |
| factor generation | #59 |
| warfarin treatment | #59 |
| bias trial | #59 |
| risk vte | #59 |
| thrombosis aged | #59 |
| mutation prothrombin | #59 |
| heterozygous factor | #59 |
| women difference | #60 |
| prevalence pulmonary | #60 |
| anticoagulants treatment | #60 |
| pulmonary embolism 95 | #60 |
| atrial fibrillation metaanalysis | #60 |
| pediatric venous thromboembolism | #60 |
| target inr | #60 |
| hemorrhage humans | #60 |
| constans | #60 |
| acute pulmonary embolism | #60 |
| fixeddose | #60 |
| awareness risk factors | #60 |
| 079 95 | #60 |
| benzimidazoles dabigatran | #61 |
| 3633 | #61 |
| free thyroxine | #61 |
| long‐term treatment | #61 |
| rosendaal | #61 |
| dvt 95 | #61 |
| tests prevalence | #61 |
| association protein | #61 |
| hypocoagulable | #61 |
| month surgery | #61 |
| perfusion ventilation | #61 |
| amuse | #61 |
| cdr score | #61 |
| combined contraceptives oral | #62 |
| ttr patients | #62 |
| human endotoxemia | #62 |
| 273 patients | #62 |
| procoagulant state | #62 |
| patients administration | #62 |
| 250 patients | #62 |
| post thrombotic | #62 |
| activated partial | #62 |
| protein fibrinogen | #62 |
| general practitioners patients | #62 |
| informatizado | #62 |
| physicians predictive | #63 |
| smoking smoking cessation | #63 |
| quantitative test | #63 |
| women mutations | #63 |
| revised geneva score | #63 |
| treatment network | #63 |
| 33 women | #63 |
| common odds ratio | #63 |
| symptoms dvt | #63 |
| cvrs | #63 |
| factor leiden risk | #63 |
| rivaroxaban lmwh | #63 |
| venous thromboembolisms | #63 |
| injection endotoxin | #63 |
| management anticoagulation | #63 |
| vte thromboprophylaxis | #63 |
| superficial vein | #64 |
| factor inhibitors | #64 |
| patients aortic valve | #64 |
| decision rules | #64 |
| selfadjustment | #64 |
| prior vte | #64 |
| oral thrombin | #64 |
| acute pulmonary | #64 |
| vkas treatment | #64 |
| postthrombotic | #64 |
| bleeding events patients | #64 |
| blinded trial | #64 |
| dvts | #64 |
| thrombophilic risk | #64 |
| heparin fondaparinux | #64 |
| cancer noncancer patients | #64 |
| treatment pad | #65 |
| accuracy diagnostic tests | #65 |
| prevalence abnormalities | #65 |
| prothrombin g20210a mutation | #65 |
| stroke thromboembolism | #65 |
| fvl vte | #65 |
| ultrasonograms | #65 |
| dvt sensitivity | #66 |
| rapid triage | #66 |
| death classification | #66 |
| 0 points | #66 |
| newer anticoagulants | #66 |
| elfa | #66 |
| female heparin | #66 |
| 95 bleeding | #66 |
| statin therapy risk | #66 |
| axa | #66 |
| risk factor thrombosis | #66 |
| standard therapy patients | #67 |
| 1127 | #67 |
| patients factor | #67 |
| rate major | #67 |
| atrial fibrillation stroke | #67 |
| patients tertiles | #67 |
| apixaban | #67 |
| ranging study | #68 |
| patients bnp levels | #68 |
| 3594 | #68 |
| coagulation fibrinolysis | #68 |
| patients benefits | #68 |
| 20210g | #68 |
| 05 95 | #68 |
| perioperative blood | #68 |
| fibrinolytic | #68 |
| 1894 | #68 |
| academic medical centre | #68 |
| postphlebitic | #69 |
| justify | #69 |
| ionis | #69 |
| certoparin | #69 |
| recurrent thrombosis patients | #69 |
| heparin ufh | #69 |
| thrombosis blood | #69 |
| plasma interleukin | #69 |
| suspected | #69 |
| enfermedad tromboembólica | #69 |
| vwfrco | #70 |
| ischemic events patients | #70 |
| rivaroxaban treatment | #70 |
| mantelhaenszel | #70 |
| aged predictive | #70 |
| α2ap | #70 |
| test patients | #70 |
| patients protein | #70 |
| gramnegative sepsis | #70 |
| fixed dose | #70 |
| withhold | #70 |
| cutoff levels | #70 |
| thrombosis recurrence | #70 |
| elevated cardiac | #70 |
| 8190 | #70 |
| major bleeding complications | #70 |
| vte vka | #71 |
| tests prospective | #71 |
| diagnostic sensitivity specificity | #71 |
| levels vwf | #71 |
| unfractionated | #71 |
| topic costs | #71 |
| asymptomatic atherosclerosis | #71 |
| thromboprophylaxis | #71 |
| plasminogen plg | #71 |
| clopidogrel placebo | #71 |
| complications hematologic | #72 |
| ddimer values | #72 |
| hf studies | #72 |
| versus vitamin | #72 |
| new anticoagulant | #72 |
| pooled rate | #72 |
| elevated factor | #72 |
| trifurcation | #72 |
| activation prothrombin | #72 |
| antithrombin iii iii | #72 |
| patients lmwh | #72 |
| viia factor | #72 |
| overt hypothyroidism | #72 |
| noacs | #73 |
| ingelheim | #73 |
| reversal agent | #73 |
| soluble fibrin | #73 |
| analysis diagnostic | #73 |
| tomography spiral | #73 |
| prolongations | #73 |
| 12 months 95 | #73 |
| ddimer measurement | #73 |
| suspected dvt | #74 |
| carriers | #74 |
| 5395 | #74 |
| 2550 | #74 |
| study selection | #74 |
| soluble thrombomodulin | #74 |
| 1732 | #74 |
| prethrombotic state | #74 |
| longterm risk | #74 |
| experimental metastasis | #74 |
| dvt study | #74 |
| 2124 | #74 |
| female hemorrhage | #74 |
| proteins patients | #74 |
| postoperative dvt | #75 |
| incidence bleeding events | #75 |
| selective factor | #75 |
| retrospective follow | #75 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| 2904 | #75 |
| thrombolytic therapy patients | #75 |
| 1334 | #75 |
| angiography ctpa | #76 |
| duration thromboprophylaxis | #76 |
| factor xii deficiency | #76 |
| early time | #76 |
| tests primary | #76 |
| risk thrombosis | #76 |
| extended anticoagulation | #76 |
| combined contraceptives | #76 |
| oral combined contraceptives | #76 |
| individual patient | #77 |
| patients secondary | #77 |
| thrombosis pregnancy | #77 |
| p023 | #77 |
| social aspects | #77 |
| boehringer | #77 |
| unprovoked | #78 |
| elevated dimer | #78 |
| arterial thromboembolism | #78 |
| 20 daily | #78 |
| arterial wall thickness | #78 |
| ipg | #78 |
| women thrombophilia | #78 |
| female fibrinolysis | #78 |
| suspected acute | #79 |
| humans pulmonary | #79 |
| vkas | #79 |
| time therapeutic | #79 |
| topic heparin | #79 |
| vte fvl | #79 |
| limulus test | #79 |
| factor adult | #79 |
| 2486 | #79 |
| efficacy agents | #79 |
| daily bid | #80 |
| validation models | #80 |
| 95 05 | #80 |
| subhazard ratio | #80 |
| alife | #80 |
| thromboembolism incidence | #80 |
| suspected cancer | #80 |
| heterozygous deficiency | #80 |
| vte rate | #80 |
| bleeding mortality | #80 |
| patient data | #80 |
| sspe patients | #80 |
| prothrombin complex concentrate | #81 |
| weitz | #81 |
| topic risk | #81 |
| vascular events | #81 |
| knee arthroplasty patients | #81 |
| systemic inflammatory | #81 |
| test evaluation | #81 |
| walking distance | #81 |
| outpatient basis | #81 |
| lmwh vte | #81 |
| 3month followup | #82 |
| mammography patients | #82 |
| thrombosis thrombophilia | #82 |
| placebo women | #82 |
| prospective validation | #82 |
| common practice | #82 |
| 50 micrograms | #82 |
| timeperiods | #82 |
| symptomatic carriers | #82 |
| thrombosis incidence | #82 |
| heparin prevention | #82 |
| thrombolytic drugs | #82 |
| clinical sign | #82 |
| posthoc analysis | #82 |
| crnmb | #82 |
| 287 | #83 |
| patients thrombi | #83 |
| elective coronary | #83 |
| dimer patients | #83 |
| 2213 | #83 |
| inhibitor dabigatran | #83 |
| bleeding women | #83 |
| bistro | #83 |
| healthcare setting | #84 |
| prophylactic dose | #84 |
| inherited thrombophilia | #84 |
| normotensive patients | #84 |
| heparin treatment | #84 |
| screening humans | #84 |
| diagnostic outcome | #84 |
| inhibitor rivaroxaban | #84 |
| duration therapy | #84 |
| peripheral vascular diseases | #85 |
| endotoxins | #85 |
| venous thrombosis patients | #85 |
| anticoagulants antiphospholipid | #85 |
| normal levels | #85 |
| thrombosis svt | #85 |
| asymptomatic dvt | #85 |
| antithrombin iii protein | #85 |
| venovenous hemofiltration | #86 |
| elevated ddimer levels | #86 |
| rhapc | #86 |
| 75 microg | #86 |
| 4576 | #86 |
| dabigatran vka | #86 |
| major bleeding warfarin | #86 |
| 10⁶ | #86 |
| clinical impact | #87 |
| vidas | #87 |
| obstetric patients | #87 |
| contact activation | #87 |
| post‐hoc analysis | #87 |
| ≤50 | #87 |
| avws | #87 |
| 95 100 | #87 |
| patients 28 | #87 |
| acute venous | #87 |
| cdr | #88 |
| internist | #88 |
| lmwhs | #88 |
| 3319 | #88 |
| treatment statins | #88 |
| washout period | #88 |
| aged multicenter | #88 |
| activation factor | #88 |
| treatment incidence | #88 |
| venographic | #88 |
| 4 points | #88 |
| unexplained recurrent | #89 |
| cytokine release | #89 |
| beta blockers | #89 |
| ventilation lung | #89 |
| smoking incidence | #89 |
| safety noacs | #89 |
| anticoagulants dabigatran | #89 |
| reversal strategies | #89 |
| costs patient | #89 |
| matisse | #89 |
| stroke bleeding | #89 |
| tests test | #89 |
| ddimer | #89 |
| vte venous thromboembolism | #89 |
| severe hf | #89 |
| rates major bleeding | #89 |
| adequate treatment | #89 |
| 2293 | #90 |
| vka dabigatran | #90 |
| outweighs | #90 |
| new patients | #90 |
| pediatric venous | #90 |
| thrombophilic risk factors | #90 |
| primary thromboprophylaxis | #90 |
| fibrinolytic factors | #90 |
| venous thrombosis risk | #90 |
| popliteal vein | #90 |
| pyridines pyridones | #91 |
| perfusion ratio | #91 |
| 60 95 | #91 |
| 20210 | #91 |
| agents hemorrhage | #91 |
| anticoagulants doacs | #91 |
| thrombosis women | #91 |
| inconvenience | #91 |
| cdrs | #91 |
| thromboembolism pregnancy | #91 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| prophylaxis incidence | #92 |
| single intravenous | #92 |
| anticoagulation reversal | #93 |
| rivaroxaban edoxaban | #93 |
| scenario analyses | #93 |
| compression patients | #93 |
| incidence knee | #93 |
| direct thrombin inhibitors | #93 |
| 95 years | #93 |
| children vte | #94 |
| vte surgery | #94 |
| heparins | #94 |
| test result | #94 |
| 1027 | #94 |
| atherogenic lipid | #94 |
| 125 patients | #94 |
| hf severity | #94 |
| patients symptomatic | #94 |
| direct oral anticoagulant | #95 |
| viia rfviia | #95 |
| 2 levels | #95 |
| european consensus statement | #95 |
| risk symptomatic | #96 |
| xii deficiency | #96 |
| fondaparinux treatment | #96 |
| ddimer level | #96 |
| efficacy rivaroxaban | #96 |
| symptomatic vte | #96 |
| 6 12 months | #96 |
| randomised crossover study | #96 |
| fibrin generation | #97 |
| invasive testing | #97 |
| symptomatic pulmonary embolism | #97 |
| pyrazoles pyridones | #97 |
| studies evaluated | #97 |
| doacs risk | #97 |
| abnormal perfusion | #97 |
| difference rates | #97 |
| haemophilia patients | #97 |
| tpa release | #97 |
| 2875 | #98 |
| hypercoagulable | #98 |
| activated protein apc | #98 |
| supervised exercise therapy | #98 |
| pregnancy postpartum period | #98 |
| essential thrombocythaemia | #98 |
| major bleed | #98 |
| simplify | #98 |
| 16slice | #98 |
| unselected | #99 |
| perfusion scintigraphy | #99 |
| probast | #99 |
| hirudin | #99 |
| lmwh warfarin | #99 |
| 2·0 | #99 |
| risk arterial | #99 |
| acute dvt | #99 |
| fatty foods | #100 |
| 3 trials | #100 |
| patient groups | #100 |
| increasing levels | #100 |
| gbd 2010 | #100 |
| previews | #100 |
| warfarin patients | #100 |
| 1116 | #100 |
| doubleblind trial | #100 |
| prevention recurrent | #100 |
| morpholines | #101 |
| factor viia | #101 |
| aptts | #101 |
| factor vii factor | #101 |
| alternative diagnosis | #102 |
| venous thromboembolism women | #102 |
| pts patients | #102 |
| 40 microg | #102 |
| 265 patients | #102 |
| enoxaparin fondaparinux | #102 |
| low pretest probability | #102 |
| cteph patients | #103 |
| therapeutic consequences | #103 |
| 338 | #103 |
| adjudicated | #103 |
| arthroscopic anterior | #103 |
| endogenous thrombin | #103 |
| pregnancy puerperium | #103 |
| doppler method | #103 |
| antithrombin iii | #104 |
| fibrin degradation products | #104 |
| term treatment | #104 |
| diagnostic imaging humans | #104 |
| partial restoration | #104 |
| assay variation | #104 |
| recurrence women | #104 |
| oral factor | #104 |
| separate analyses | #104 |
| absolute increase | #104 |
| heparin pregnancy | #104 |
| apparent increase | #104 |
| 7 children | #105 |
| embryo loss | #105 |
| 1089 | #105 |
| conventional therapy patients | #105 |
| fibrinolytic systems | #106 |
| thromboprophylaxis patients | #106 |
| chest ray | #106 |
| 2479 | #106 |
| thrombophilia | #106 |
| hospitalized patients hf | #106 |
| 314 | #106 |
| study total | #106 |
| essentials | #106 |
| blind double | #106 |
| elevated levels | #106 |
| thrombosis age | #106 |
| simplified version | #107 |
| survival cancer patients | #107 |
| topic recurrence | #107 |
| thromboembolic | #107 |
| definition classification | #107 |
| ddimer levels | #107 |
| vte risk | #107 |
| grade 1c | #108 |
| cardiovascular death stroke | #108 |
| human volunteers | #108 |
| post thrombotic syndrome | #108 |
| specific subgroups | #108 |
| noncancer patients | #108 |
| patients cancer | #108 |
| 500μg | #109 |
| routine coagulation | #109 |
| 039 | #109 |
| anticoagulants cohort | #109 |
| evaluation studies | #109 |
| embolism treatment | #109 |
| factor mutation | #109 |
| 1235 | #109 |
| synthetic pentasaccharide | #109 |
| viia | #109 |
| thrombin antithrombin | #109 |
| antiplasmin | #110 |
| primary safety | #110 |
| embolism quality | #110 |
| inferiority trial | #110 |
| subsequent pregnancy | #110 |
| cancer activity | #110 |
| vka doac | #110 |
| thrombosis treated | #110 |
| negative predictive 100 | #111 |
| humans intermittent | #111 |
| predefined | #111 |
| siset | #111 |
| obstetric complications | #111 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| comparison control | #111 |
| chromogenic | #112 |
| emergency situations | #112 |
| patients ventricular dysfunction | #112 |
| thromboembolic diseases | #112 |
| recurrence treatment | #112 |
| rivaroxaban enoxaparin | #112 |
| risk rivaroxaban | #112 |
| epidemiology risk factors | #112 |
| efficacy prevention | #112 |
| patients 70 | #112 |
| publication anticoagulants | #112 |
| topic guidelines | #112 |
| metabolic response | #113 |
| lmwh risk | #113 |
| nonionic contrast | #113 |
| inappropriate treatment | #113 |
| patients nephrotoxicity | #113 |
| heterozygous carriers | #113 |
| 0·0 | #114 |
| postphlebitic syndrome | #114 |
| study centre | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| total knee replacement | #114 |
| dialysers | #114 |
| global public | #115 |
| 393 | #115 |
| hyperhomocysteinaemia | #115 |
| fibrinogen vwf | #115 |
| patients recurrent | #115 |
| positive predictive values | #115 |
| reference standard | #116 |
| heparin warfarin | #116 |
| effects tnf | #116 |
| topic dabigatran | #116 |
| agents heparin | #116 |
| major bleeding 95 | #116 |
| women severe preeclampsia | #116 |
| vte data | #116 |
| computed tomography patients | #116 |
| life treatment | #116 |
| anticoagulants arthroplasty | #116 |
| vte children | #117 |
| protein resistance | #117 |
| 2460 | #117 |
| fibrinolytic parameters | #117 |
| women caesarean | #117 |
| protein inhibitor pci | #117 |
| arthroscopies | #117 |
| vte complications | #117 |
| patients extensive | #118 |
| proximal dvt | #118 |
| 4118 | #118 |
| arterial thrombosis patients | #118 |
| 2744 | #118 |
| autopsyconfirmed | #118 |
| patients doac | #119 |
| compared warfarin | #119 |
| incidence pulmonary embolism | #119 |
| compression stockings | #119 |
| humans leg | #119 |
| lactoferrin leukocyte | #120 |
| mortality diseases | #120 |
| thrombosis study | #120 |
| dabigatran factor | #120 |
| risk thromboembolism | #120 |
| previous vte | #120 |
| healthy humans | #120 |
| acquired deficiency | #120 |
| months follow | #120 |
| rivaroxaban patients | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| patients 6 | #122 |
| oral hormonal | #122 |
| anti factor | #122 |
| studies venous | #122 |
| fatal pulmonary embolism | #122 |
| early dynamics | #123 |
| heparin | #123 |
| heparin hirudin | #123 |
| acute infection | #123 |
| 100 patients | #123 |
| venous thromboembolism pregnancy | #123 |
| placebo standard | #123 |
| minor bleeding | #123 |
| factor xia | #123 |
| statin risk | #124 |
| treatment data | #124 |
| atherogenic lipid profile | #124 |
| vte lmwh | #124 |
| association level | #124 |
| ft4 levels | #124 |
| thrombophilia pregnancy | #124 |
| elevated liver enzymes | #125 |
| thromboembolism recurrence | #125 |
| peripheral arterial disease | #125 |
| fibrinolysis inhibitor | #125 |
| bayer | #125 |
| puerperal disorders | #125 |
| treatment indication | #125 |
| skin perfusion | #125 |
| diseases mortality | #125 |
| nonsignificantly | #125 |
| incidence thrombosis | #125 |
| intravenous heparin | #125 |
| doacs treatment | #126 |
| upper extremity | #126 |
| distal dvt | #126 |
| occurrence vte | #127 |
| thromboprophylaxis lmwh | #127 |
| performance scores | #127 |
| patients ventilation | #127 |
| unacceptably | #127 |
| patients permanent | #127 |
| marder | #127 |
| 50 age | #128 |
| prevention | #128 |
| direct factor | #128 |
| patients conventional therapy | #128 |
| resistance apc | #128 |
| development vte | #128 |
| treatment months | #128 |
| venous thromboembolism risk | #128 |
| riete registry | #129 |
| ctrough | #129 |
| mortality cancer patients | #129 |
| 1041 | #129 |
| 060 | #129 |
| elevated biomarkers | #129 |
| 220 | #130 |
| hospital discharge records | #130 |
| day 10 | #130 |
| plaster cast | #130 |
| internists | #130 |
| anticoagulants antithrombins | #130 |
| patients episode | #130 |
| 194 patients | #130 |
| pooled incidence | #131 |
| tests specificity | #131 |
| linear interpolation | #131 |
| obviating | #131 |
| 05 patients | #131 |
| long‐term clinical outcomes | #131 |
| hypocoagulability | #132 |
| hoc analysis | #132 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| fxa inhibitors | #133 |
| 80 anticoagulants | #133 |
| avidin | #133 |
| enoxaparin treatment | #133 |
| cha2ds2vasc | #133 |
| started | #133 |
| direct inhibitors | #133 |
| risk pad | #134 |
| pulmonary angiography patients | #134 |
| embolism acute | #134 |
| instituted | #134 |
| rco vwf | #134 |
| selectin levels | #134 |
| anticoagulant prophylaxis | #135 |
| prevalence dvt | #135 |
| activator plasminogen | #135 |
| bnp concentration | #135 |
| east asian patients | #136 |
| clinical prediction | #136 |
| severe pph | #136 |
| followup patients | #136 |
| 0056 | #136 |
| months anticoagulation | #136 |
| apixaban edoxaban | #136 |
| thrombotic syndrome | #136 |
| 99 patients | #137 |
| sequential application | #137 |
| acquired thrombophilia | #137 |
| phase 3 trials | #137 |
| 2283 | #137 |
| point‐of‐care | #137 |
| diagnostic work | #137 |
| factor prothrombin | #137 |
| national guidelines | #138 |
| studies mortality | #138 |
| antidote | #138 |
| intravascular coagulation dic | #138 |
| complete inhibition | #138 |
| bleeding warfarin | #138 |
| enhanced factor | #138 |
| 2465 | #139 |
| 3 weeks | #139 |
| 95 major bleeding | #139 |
| oral anticoagulant treatment | #139 |
| risk fatal | #139 |
| direct inhibitor | #139 |
| factor viii factor | #139 |
| patients comparison | #139 |
| reproducibility risk | #139 |
| 0114 | #140 |
| 80 cohort | #140 |
| 12 95 | #140 |
| 20 iu | #140 |
| dvt incidence | #140 |
| distal deep | #140 |
| vwf rco | #140 |
| human activated | #140 |
| ottawa | #140 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| antidotes | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| ischaemic events | #143 |
| points 95 | #143 |
| active malignancy | #143 |
| geneva | #143 |
| escherichia humans | #143 |
| jugular veins | #143 |
| warfarin administration | #143 |
| treatment pulmonary | #143 |
| pregnancy female humans | #144 |
| topic practice patterns | #144 |
| compared treatment | #144 |
| doac treatment | #144 |
| management vte | #144 |
| postoperative venous | #144 |
| fatal pulmonary | #144 |
| filters venous | #145 |
| hyperthyroxinemia | #145 |
| serial testing | #145 |
| patient populations | #145 |
| dose rivaroxaban | #145 |
| referred patients | #145 |
| thrombosis model | #145 |
| derived microvesicles | #146 |
| protein factor | #146 |
| death cancer patients | #146 |
| months treatment | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| rebuttal | #148 |
| embolism diagnosis | #148 |
| acute medical illness | #148 |
| partial thromboplastin | #148 |
| antithrombotic drugs | #148 |
| 2076 | #148 |
| intention treat | #148 |
| 10 years patients | #148 |
| long‐acting | #148 |
| relevant publications | #149 |
| risk subgroups | #149 |
| vte hospitalization | #149 |
| 0·45 | #149 |
| procoagulant | #149 |
| individual patient data | #149 |
| diagnostic score | #149 |
| thrombocyte | #149 |
| dimer level | #150 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| additional imaging | #151 |
| coagulation dic | #151 |
| continuous venovenous | #152 |
| bleeding patients | #152 |
| patient eligibility | #152 |
| patients primary outcome | #152 |
| longterm treatment | #152 |
| hypercoagulable state | #153 |
| point systems | #153 |
| thrombosis prevention | #153 |
| extracorporeal circuit | #153 |
| cardiopulmonary bypass surgery | #153 |
| dimer levels | #154 |
| thrombosis factor | #154 |
| activity mortality | #154 |
| bleeding scores | #154 |
| direct thrombin | #154 |
| active cancer | #154 |
| angioplasty patients | #154 |
| tomography patients | #155 |
| states venous | #155 |
| thromboembolic event | #155 |
| warfarin apixaban | #155 |
| curve sensitivity | #155 |
| drug factor | #155 |
| fiia | #155 |
| coagulant activity | #156 |
| fvl | #156 |
| stockings | #156 |
| 09 | #156 |
| recurrent symptoms | #156 |
| daily oral | #156 |
| patients gastrointestinal | #156 |
| enoxaparin dose | #156 |
| vte treatment | #156 |
| increased thrombin | #157 |
| hemodynamically | #157 |
| cross‐sectional survey | #157 |
| prophylaxis patients | #157 |
| dfl | #158 |
| underlying malignancy | #158 |
| duration anticoagulation | #158 |
| months chemotherapy | #158 |
| 97 | #158 |
| 2126 | #158 |
| adjusted relative risk | #159 |
| increased risk thrombosis | #159 |
| plasma dimer | #160 |
| schering | #160 |
| 120 minutes | #160 |
| guidelines prevention | #160 |
| 145 patients | #160 |
| children fh | #160 |
| antithrombotic efficacy | #160 |
| thrombotic disorders | #160 |
| antagonists patients | #161 |
| prophylactics | #161 |
| pvo | #161 |
| women time | #162 |
| incidence vte | #162 |
| 2206 | #162 |
| lysine analogues | #162 |
| patients imaging | #162 |
| venous thrombus | #163 |
| rates vte | #163 |
| factors bleeding | #163 |
| coagulation blood | #163 |
| lmwh therapy | #163 |
| increased plasma levels | #163 |
| strain gauge | #163 |
| imaging test | #163 |
| 198 patients | #163 |
| age comorbidity | #164 |
| justified | #164 |
| inborn humans | #164 |
| observer variability | #164 |
| 028 | #164 |
| mutation factor | #165 |
| subhazard | #165 |
| patients enoxaparin | #165 |
| relatives patients | #165 |
| pravastatin therapy | #166 |
| phlebography | #166 |
| stockings compression | #166 |
| strategies patients | #166 |
| viii factor | #166 |
| management venous thromboembolism | #166 |
| microvascular thrombosis | #166 |
| ankle brachial abi | #167 |
| recurrent thrombosis | #167 |
| 3658 | #167 |
| thrombin venous | #167 |
| syndrome pts | #168 |
| double heterozygosity | #168 |
| warfarin | #168 |
| cvcs | #168 |
| treatment 3 months | #168 |
| cstatistics | #168 |
| recurrent acute | #168 |
| current clinical practice | #168 |
| therapeutic range | #169 |
| fold increased | #169 |
| postthrombotic syndrome pts | #169 |
| 3 12 | #169 |
| risk profile | #169 |
| patients infections | #169 |
| preexistent | #169 |
| cart patients | #170 |
| heavy menstrual bleeding | #170 |
| interobserver agreement | #170 |
| thrombosis cancer | #170 |
| postoperative blood loss | #170 |
| recombinant factor | #171 |
| aged algorithms | #171 |
| venous thrombotic events | #171 |
| 57 years | #171 |
| adamts‐13 | #171 |
| patients blood transfusion | #172 |
| clinical trials patients | #172 |
| antifibrinolytic | #172 |
| pulmonology | #172 |
| lmw heparin | #172 |
| vaginal bleeding | #172 |
| risk factors patients | #172 |
| bleeds | #173 |
| pulmonary | #173 |
| hospitalized medical patients | #173 |
| inr | #173 |
| patients initial | #174 |
| laboratory monitoring | #174 |
| arterial occlusions | #174 |
| bleeding tendency | #174 |
| clinically bleeding | #174 |
| reocclusion | #175 |
| arterial venous | #175 |
| vte common | #175 |
| data control | #175 |
| fragment 1 | #175 |
| picotamide | #177 |
| mitsubishi | #177 |
| prothrombin | #177 |
| intention analysis | #178 |
| short‐ | #178 |
| aspirin ticlopidine | #178 |
| 122 | #178 |
| hyperthyroidism hypothyroidism | #178 |
| oral female humans | #179 |
| noninferior | #179 |
| vte event | #179 |
| concomitance | #179 |
| baseline day | #179 |
| patients deficiency | #180 |
| referral bias | #180 |
| ventilation perfusion | #180 |
| thromboplastin time | #180 |
| isth | #180 |
| additional risk factors | #180 |
| aged partial | #181 |
| testing patients | #182 |
| antithrombin | #182 |
| acute episode | #182 |
| painkillers | #182 |
| biological variation | #183 |
| hyperhomocysteinemic | #183 |
| patients major | #183 |
| 2–4 | #183 |
| pregnancy vte | #184 |
| subsequent diagnosis | #184 |
| treat analysis | #184 |
| coagulation factors | #184 |
| thromboinflammation | #184 |
| incidental | #184 |
| prognosis pulmonary | #184 |
| n110 | #184 |
| 4150 | #184 |
| antithrombin iii atiii | #184 |
| risk bleeding | #184 |
| deficient patients | #185 |
| vte age | #185 |
| patients intensive units | #186 |
| symptomatic | #186 |
| hemostatic effects | #186 |
| studies heparin | #186 |
| live birth rate | #186 |
| brain natriuretic | #186 |
| anticoagulated | #186 |
| patients thromboprophylaxis | #186 |
| risk composite | #187 |
| patients haemophilia | #187 |
| antifibrinolytic agents | #187 |
| cutoff level | #187 |
| safety apixaban | #187 |
| 926 | #188 |
| doacs vkas | #188 |
| prevalence cancer | #188 |
| absolute rate | #188 |
| humans international | #188 |
| spontaneous rupture | #188 |
| ratio inr | #188 |
| willebrand factor antigen | #189 |
| fibrinolysis | #189 |
| clinical validity | #189 |
| blood loss patients | #189 |
| riete | #189 |
| 64slice | #189 |
| patients netherlands | #189 |
| heparin administration | #189 |
| viia female | #189 |
| current views | #190 |
| ccus | #190 |
| thrombosis patients | #190 |
| ischemic event | #190 |
| anticoagulant drugs | #190 |
| score patients | #191 |
| gogh | #191 |
| attending physicians | #191 |
| acute thrombosis | #191 |
| 07 | #191 |
| venous outflow | #191 |
| stroke systemic | #192 |
| 1495 | #192 |
| 058 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| blood coagulation | #194 |
| 070 | #194 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| heparin patients | #194 |
| 65 months | #195 |
| risk major | #195 |
| recurrent ischemic events | #195 |
| antixa levels | #195 |
| antagonist treatment | #195 |
| target range | #195 |
| complications cardiovascular | #196 |
| abnormal test | #196 |
| coagulation status | #196 |
| 29 95 | #196 |
| treatment groups patients | #198 |
| vii rfviia | #198 |
| ate | #198 |
| difference treatment | #198 |
| sew2871 | #198 |
| vwf adamts13 | #198 |
| coagulation monitoring | #199 |
| cachectin | #199 |
| patient diagnosis | #199 |
| incidence cardiovascular events | #200 |
| patients 12 months | #200 |
| screening patients | #200 |
| obese controls | #200 |
| patients abnormal | #201 |
| thromboembolic disease | #201 |
| validation sets | #201 |
| vte incidence | #201 |
| thrombin factor | #201 |
| arterial thrombosis | #202 |
| peritoneovenous | #202 |
| 17 95 | #202 |
| johnson | #202 |
| heparin dose | #203 |
| worldwide survey | #203 |
| invitees | #203 |
| induced activation | #203 |
| symptomatic pad | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| low incidence | #205 |
| stroke systemic embolism | #205 |
| thrombophilia risk | #205 |
| 0 95 | #205 |
| period time | #205 |
| extended thromboprophylaxis | #205 |
| venous ultrasonography | #206 |
| data synthesis | #206 |
| varese | #206 |
| patients anticoagulant therapy | #206 |
| fgt | #206 |
| methods consecutive | #207 |
| platelet activation patients | #207 |
| 06 | #207 |
| objectively | #207 |
| death female humans | #207 |
| desogestrel | #207 |
| fviii | #207 |
| cardiologist | #207 |
| algorithms anticoagulants | #207 |
| imt patients | #207 |
| systematic review studies | #207 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| bleeding compared | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| women frequency | #210 |
| tgt | #210 |
| antixa activity | #210 |
| hirudins | #210 |
| ioxaglate | #211 |
| toxaemia | #211 |
| stocking | #211 |
| systemic embolism patients | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| topic practice | #214 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| thrombin inhibition | #215 |
| factors vte | #215 |
| current developments | #215 |
| studies rivaroxaban | #215 |
| standard duration | #215 |
| deamino | #216 |
| warfarin stroke | #216 |
| duplex venous | #216 |
| community hospital | #216 |
| betatg | #216 |
| undergoing total | #217 |
| mildest | #217 |
| diagnostic algorithm | #217 |
| obviates | #217 |
| studies difference | #217 |
| conclusive evidence | #218 |
| cstatistic | #218 |
| g20210a | #218 |
| plasminogen activator inhibitor | #218 |
| npv 100 | #218 |
| cancer | #219 |
| deamino arginine | #219 |
| patients cart | #219 |
| 077 95 | #219 |
| data extraction | #220 |
| techniques female | #220 |
| viii female | #220 |
| vii factor | #220 |
| hip replacement surgery | #220 |
| postoperative vte | #221 |
| healthy human subjects | #221 |
| preventive measures | #221 |
| hmvec | #221 |
| heparin humans | #221 |
| proximally | #222 |
| vte events | #222 |
| apc resistance | #222 |
| engl | #223 |
| substantial proportion | #223 |
| pulmonologists | #223 |
| 1541 | #223 |
| 1 january | #223 |
| subsequent cancer | #224 |
| thromboendarterectomy | #224 |
| protein pathway | #224 |
| topic factor | #224 |
| thrombosis warfarin | #225 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| kruskalwallis | #225 |
| org | #225 |
| extremity amputation | #226 |
| vascular events patients | #226 |
| 0·67 | #226 |
| inr monitoring | #226 |
| 16 95 | #226 |
| acute medical | #227 |
| tests diagnosis | #227 |
| haemostasis | #227 |
| 35 ± | #227 |
| ipe | #228 |
| mild hyperhomocysteinemia | #228 |
| residual thrombus | #229 |
| scant | #229 |
| dalteparin | #229 |
| cgp | #229 |
| advocated | #230 |
| 037 | #230 |
| major orthopaedic surgery | #231 |
| resource utilisation | #231 |
| equinox | #231 |
| urosepsis | #231 |
| 6 studies | #231 |
| habitual abortion | #231 |
| patients discontinuation | #231 |
| severe preeclampsia | #231 |
| ft4 | #231 |
| thiazoles | #231 |
| aspirin dipyridamole | #232 |
| patients warfarin | #232 |
| recurrence risk factors | #233 |
| surgical embolectomy | #233 |
| endogenous thrombin potential | #233 |
| anticoagulant effects | #233 |
| dimer | #233 |
| cancer prevalence | #233 |
| humans netherlands | #233 |
| effective alternative | #234 |
| graduated compression | #235 |
| doac | #235 |
| prothrombotic state | #235 |
| brain natriuretic peptide | #236 |
| venous thromboembolic events | #236 |
| humans meta | #236 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| predictive tests | #238 |
| patients vkas | #238 |
| 6500 | #238 |
| 009 | #238 |
| crossover study | #239 |
| factor tnf | #239 |
| anticoagulants aspirin | #239 |
| rational approach | #239 |
| factor viii fviii | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| hip knee arthroplasty | #241 |
| aspirin heparin | #241 |
| 045 | #241 |
| bleeding incidence | #242 |
| time therapeutic range | #242 |
| pivotal trials | #243 |
| prothrombin fragment | #243 |
| patients intermittent claudication | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| children neonates | #246 |
| casecontrol | #246 |
| vte cases | #246 |
| thrombogenesis | #246 |
| 23 95 | #247 |
| warfarin aged | #247 |
| lipoproteina levels | #247 |
| antithrombotic | #247 |
| coronary anticoagulants | #248 |
| patients solid tumours | #248 |
| committees | #248 |
| treatment compared | #248 |
| anti activity | #248 |
| multiple comorbidities | #249 |
| diagnostic models | #249 |
| score risk | #249 |
| bleeding rates | #249 |
| ischemic strokes | #250 |
| fv leiden | #250 |
| protein risk | #250 |
| ioxaglic | #250 |
| microthrombosis | #251 |
| patients contraindications | #251 |
| finalized | #251 |
| 8595 | #251 |
| simplification | #252 |
| vkas doacs | #252 |
| somit | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| medea | #256 |
| haul | #256 |
| activation humans | #256 |
| activity assay | #257 |
| q24h | #257 |
| continuous intravenous | #257 |
| bleeding risk | #257 |
| cost‐effectiveness | #257 |
| clinical utility | #257 |
| ctpa | #258 |
| fibrin degradation | #258 |
| patient subgroups | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| dvt risk | #260 |
| sspe | #260 |
| thrombus size | #261 |
| noncarriers | #261 |
| toxicosis | #261 |
| heparin dosing | #261 |
| patients hospitalization | #262 |
| risk pulmonary | #263 |
| optimal duration | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| relation time | #269 |
| lysis time | #269 |
| malignancy patients | #269 |
| propeptide | #269 |
| versus aspirin | #269 |
| randomised cross | #269 |
| discontinuing | #270 |
| exclusion | #270 |
| protein patients | #270 |
| single test | #270 |
| platelet serotonin | #271 |
| 3·0 | #271 |
| protein apc | #271 |
| orthopaedic patients | #271 |
| hormonal replacement therapy | #271 |
| thrombosis inflammation | #271 |
| clopidogrel ticlopidine | #272 |
| groups levels | #272 |
| bleeding patient | #272 |
| patients combination | #272 |
| vte recurrence | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| prevalence pad | #274 |
| risk levels | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| international normalized | #275 |
| performance score | #275 |
| parenteral nutrition patients | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| smoking hypertension | #277 |
| time aptt | #277 |
| normalized ratio | #278 |
| imaging sensitivity | #278 |
| dose reduction | #278 |
| aptt | #279 |
| blood test | #279 |
| rco | #279 |
| exclusion criteria | #280 |
| hospitalized medical | #280 |
| partial thromboplastin time | #280 |
| intracranial hemorrhage patients | #280 |
| propositi | #280 |
| obviate | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| diagnostic sensitivity | #283 |
| thyroid diseases | #283 |
| puerperal | #283 |
| presentation patients | #283 |
| neutrophil degranulation | #283 |
| noninferiority margin | #284 |
| test characteristics | #284 |
| favor | #284 |
| departments | #284 |
| outpatient treatment | #284 |
| animals anticoagulants | #284 |
| major orthopaedic | #285 |
| plasma bnp | #286 |
| 2630 | #286 |
| gentamicin treatment | #286 |
| patients apixaban | #286 |
| patients pancreatic cancer | #287 |
| clinically | #287 |
| disseminated intravascular | #287 |
| subdistribution | #287 |
| levels measured | #287 |
| 227 | #288 |
| oral combined | #288 |
| premature atherosclerosis | #288 |
| md patients | #288 |
| vte women | #289 |
| substantiation | #289 |
| clot lysis | #289 |
| cvt patients | #289 |
| vte rates | #289 |
| 0·50 | #290 |
| n59 | #290 |
| thrombin time | #290 |
| current clinical | #291 |
| extracted data | #291 |
| carriers mutation | #291 |
| 016 | #291 |
| oral contraceptives | #291 |
| 2 studies | #292 |
| activator inhibitor | #292 |
| willebrand disease vwd | #292 |
| 1603 | #292 |
| 1000 personyears | #293 |
| patients dabigatran | #293 |
| plasmin activity | #293 |
| pentasaccharide | #293 |
| adverse outcome patients | #293 |
| patients rivaroxaban | #294 |
| lower extremities | #294 |
| cardiac troponin ctnt | #294 |
| tissuetype plasminogen activator | #294 |
| scenario analysis | #295 |
| 1025 | #295 |
| extremity dvt | #295 |
| peripheral vascular | #296 |
| classified | #296 |
| coagulation factor viii | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| thrombocytes | #298 |
| specificity npv | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| thromboglobulin | #302 |
| toxemia | #302 |
| subclinical thyroid dysfunction | #302 |
| aged neoplasms | #302 |
| 155 patients | #302 |
| absolute difference | #304 |
| 1214 | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| surgery day | #310 |
| hematologic pregnancy | #310 |
| patients 100 | #311 |
| clinical presentation | #311 |
| percentage points | #311 |
| antithrombins blood | #311 |
| 105 patients | #311 |
| 598 | #312 |
| leg male | #312 |
| negative reactions | #313 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| obesity risk factor | #313 |
| diagnosis | #314 |
| funding | #315 |
| heparin aspirin | #315 |
| puerperium | #315 |
| postpartum haemorrhage | #315 |
| cardiologists | #315 |
| therapeutic dose | #316 |
| apixaban versus | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| 0·92 | #318 |
| deciding | #318 |
| safety outcomes | #319 |
| failure rates | #319 |
| decision model | #319 |
| influenza infections | #320 |
| patients pregnancy | #320 |
| catheter thrombosis | #320 |
| 1731 | #320 |
| bnp levels | #320 |
| combined administration | #320 |
| ventricular dysfunction patients | #321 |
| patients noacs | #322 |
| intermediate phenotype | #322 |
| difference risk | #322 |
| additional data | #322 |
| peripheral arterial | #324 |
| inrs | #324 |
| glaxosmithkline | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| 122 patients | #326 |
| blood coagulation factor | #326 |
| mechanical heart valves | #326 |
| pulmonary embolus | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| pregnancy outcome women | #331 |
| vitamin administration | #331 |
| new oral | #332 |
| analysis trials | #333 |
| 95 percent | #333 |
| embase databases | #333 |
| n69 | #333 |
| incidences | #334 |
| complicate | #334 |
| 95 confidence limits | #334 |
| minor effects | #334 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| central venous catheter | #336 |
| recurrent | #337 |
| plethysmographic | #337 |
| total hip replacement | #337 |
| 035 | #337 |
| 2 points | #337 |
| 065 | #337 |
| coagulation abnormalities | #338 |
| aged netherlands | #338 |
| outpatient management | #338 |
| fatal bleeding | #338 |
| placebo trials | #339 |
| noacs warfarin | #339 |
| prospective clinical study | #339 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| 024 | #340 |
| 217 | #341 |
| coagulation markers | #341 |
| activatable | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| splanchnic vein thrombosis | #345 |
| antithrombotic strategies | #345 |
| vte prevention | #345 |
| rfviia | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| 073 | #347 |
| cochrane central | #348 |
| 044 | #348 |
| chads2 | #349 |
| bsf | #349 |
| 2575 | #349 |
| tafia | #350 |
| trousseau | #350 |
| brain predictive | #350 |
| randomized studies | #350 |
| factor viii | #351 |
| 013 | #351 |
| versus warfarin | #351 |
| anticoagulants noacs | #352 |
| selection bias | #352 |
| dermatan sulphate | #352 |
| factor activation | #352 |
| 1590 | #353 |
| vein | #353 |
| relative efficacy | #353 |
| oral anticoagulant therapy | #353 |
| 5075 | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| tests prospective studies | #357 |
| categorised | #357 |
| post hoc | #357 |
| intestinal microbiome | #357 |
| 127 patients | #358 |
| sucra | #360 |
| pilots | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| humans risk | #365 |
| conventional therapy | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| patients 3 | #368 |
| infrainguinal | #368 |
| thrombin inhibitor | #369 |
| influenza infection | #370 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| venous stasis | #371 |
| endotoxin infusion | #371 |
| 803 | #372 |
| 055 | #372 |
| recombinant activated | #373 |
| clinical suspicion | #373 |
| patients svt | #373 |
| aprotinin blood | #373 |
| knee surgery | #373 |
| patients scores | #374 |
| helical computed tomography | #374 |
| human cytomegalovirus infection | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| stroke venous | #380 |
| contraceptives oral | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| standardized questionnaire | #384 |
| thromboembolic complications | #384 |
| reassessed | #384 |
| 0·8 | #384 |
| multivariate regression analysis | #384 |
| systemic activation | #385 |
| alpha2m | #385 |
| surrogate outcome | #386 |
| bleeding events | #386 |
| conference proceedings | #386 |
| sensitivity npv | #387 |
| cumulative incidences | #387 |
| antithrombins | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| safety rivaroxaban | #389 |
| 880 | #389 |
| referred | #389 |
| systemic embolism | #389 |
| vitt | #390 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| drug prescription | #391 |
| abi | #391 |
| increased bleeding | #391 |
| postop | #391 |
| biosis | #391 |
| comparison patients | #391 |
| patients chest | #392 |
| time presentation | #392 |
| topic female humans | #392 |
| kappa values | #393 |
| factors thrombosis | #393 |
| clinical score | #394 |
| background patients | #394 |
| injections intravenous | #394 |
| pulmonary emboli | #394 |
| 007 | #395 |
| 95 12 | #396 |
| bleeding event | #396 |
| popliteal | #396 |
| factors factor | #397 |
| 665 | #397 |
| embolic events | #397 |
| hirudins humans | #397 |
| replacement surgery | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| patients risk | #400 |
| echography | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| controversy | #403 |
| dabigatran | #403 |
| increased risk vte | #403 |
| massive pulmonary embolism | #405 |
| treatment patient | #406 |
| 2215 | #406 |
| thrombolytic agents | #406 |
| 075 | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| patients assigned | #411 |
| noacs patients | #411 |
| fviii levels | #411 |
| safety combination | #411 |
| transfusion patients | #412 |
| 20 microg | #412 |
| major risk factor | #412 |
| coagulation patients | #414 |
| euthyroidism | #414 |
| maastricht | #414 |
| xii | #415 |
| hypocortisolism | #415 |
| aged odds | #415 |
| deserve | #416 |
| intravascular coagulation | #416 |
| pai1 levels | #416 |
| dose heparin | #416 |
| 95 10 | #417 |
| comparable | #417 |
| data risk | #417 |
| 95 | #418 |
| pretest probability | #418 |
| carotid femoral | #418 |
| 269 | #419 |
| dermatan | #419 |
| risk factors thrombosis | #419 |
| xia | #420 |
| ototoxicity | #420 |
| fibrillation risk | #421 |
| 1989 | #422 |
| tests radiography | #422 |
| fibrillation clinical | #422 |
| 2850 | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| adjunct | #426 |
| randomised double | #426 |
| fii | #426 |
| cancer cohort | #426 |
| consecutive | #427 |
| activated factor | #427 |
| excessive bleeding | #428 |
| plg | #428 |
| daily practice | #428 |
| conferences | #428 |
| daily clinical practice | #429 |
| idiopathic myelofibrosis | #429 |
| patients testing | #429 |
| undergoing elective | #429 |
| prolactin levels | #429 |
| 1904 | #430 |
| heparinoids | #431 |
| rule | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| blood cultures | #436 |
| firstdegree relatives patients | #436 |
| bolus injection | #437 |
| 059 | #437 |
| composite point | #439 |
| dose adjustment | #439 |
| proven | #439 |
| prostatic cancer | #439 |
| women compared | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| 074 | #442 |
| rate vte | #442 |
| standard therapies | #444 |
| –control study | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| utrecht | #449 |
| patients parenteral nutrition | #449 |
| 58 | #449 |
| hellp | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| aspirin risk | #453 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| thrombin generation | #453 |
| 30 40 | #454 |
| portal blood | #454 |
| placebo day | #454 |
| factor xii | #454 |
| microthrombi | #455 |
| 026 | #455 |
| 12week | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| onwards | #457 |
| dicumarol | #457 |
| squibb | #457 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| iii complexes | #458 |
| svt | #460 |
| recommend | #460 |
| plasma lipoprotein | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| hip arthroplasty replacement | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| gp iib | #464 |
| studies ultrasonography | #464 |
| patients values | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| intimamedia thickness | #468 |
| prophylaxis | #468 |
| patients nsaids | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| inr patients | #470 |
| 077 | #470 |
| test probability | #470 |
| roc analysis | #470 |
| hemihepatectomy | #470 |
| placebo recipients | #471 |
| prophylactic anticoagulation | #472 |
| case control study | #472 |
| hypercoagulability | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| heterozygote humans | #475 |
| endotoxemia | #475 |
| intermittent pneumatic | #475 |
| 15 95 | #475 |
| plethysmograph | #475 |
| patients heparin | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| patients score | #479 |
| 08 | #479 |
| versus standard | #480 |
| hit patients | #481 |
| thrombosis cvt | #481 |
| acutely | #481 |
| advisory | #482 |
| postoperative blood | #482 |
| 1162 | #482 |
| transportability | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| travel | #488 |
| silent | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| residual risk | #493 |
| new therapy | #493 |
| treatment period | #493 |
| p00007 | #493 |
| pan troglodytes | #493 |
| hemophilic | #493 |
| vcf | #494 |
| activated protein | #495 |
| favour | #496 |
| dose oral | #496 |
| replacement hip arthroplasty | #496 |
| heterozygote | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| discriminative ability | #498 |
| willebrand disease | #498 |
| blockages | #498 |
| risk factors stroke | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| subcategories | #503 |
| ft4 tsh | #503 |
| deficiencies | #503 |
| rapid decrease | #504 |
| complications pulmonary | #505 |
| 1107 | #505 |
| nondiagnostic | #505 |
| patients referred | #505 |
| 310 | #506 |
| net clinical | #506 |
| nonionic | #507 |
| day surgery | #507 |
| oftentimes | #507 |
| inhibitors rivaroxaban | #508 |
| aminocaproates | #509 |
| 13 95 | #509 |
| guidelines diagnosis | #509 |
| contraceptives | #509 |
| coagulation tests | #509 |
| angiography patients | #510 |
| degradation products | #510 |
| thrombosis animals | #510 |
| new oral anticoagulants | #510 |
| viii fviii | #511 |
| epiphenomenon | #512 |
| 019 | #512 |
| serial | #513 |
| highintensity | #514 |
| interim analysis | #514 |
| 056 | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| sensitivity diagnosis | #518 |
| thrombophilia thrombosis | #518 |
| bleeding outcomes | #518 |
| thrombotic diseases | #518 |
| protein antithrombin | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| 1599 | #521 |
| 8090 | #521 |
| duration intensity | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| convincing | #529 |
| 923 | #529 |
| 378 | #529 |
| 051 | #529 |
| fatal | #530 |
| health female | #530 |
| thrombosis hemostasis | #531 |
| medically patients | #531 |
| humans postoperative | #531 |
| betaalanine | #531 |
| intensive units icu | #532 |
| 068 | #532 |
| thrombosis risk | #532 |
| ≥50 years | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| humans neoplasms | #538 |
| 449 | #538 |
| patients idiopathic | #538 |
| cbo | #539 |
| concise | #539 |
| ddavp | #539 |
| comprehensive search | #539 |
| diagnostic accuracy studies | #540 |
| diagnosis acute | #540 |
| clinical review | #540 |
| patients eligible | #543 |
| thrombotic risk | #543 |
| bleeding episodes | #543 |
| 234 | #543 |
| vascular obstruction | #543 |
| conventional treatment | #543 |
| jak2 mutation | #544 |
| 00 | #544 |
| coagulative | #544 |
| pad abi | #544 |
| v617f | #545 |
| prospective cohort study | #545 |
| perc | #545 |
| hellp syndrome | #545 |
| association statin | #546 |
| screening strategies | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| adequate | #549 |
| 95 difference | #549 |
| overt | #549 |
| platelet inhibitors | #550 |
| reviewers | #550 |
| percent patients | #550 |
| conduction anesthesia | #550 |
| cancer type | #550 |
| 1103 | #550 |
| management bleeding | #552 |
| day patients | #552 |
| amsterdam | #552 |
| studies sensitivity | #552 |
| 500 patients | #552 |
| careful | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| 66 patients | #558 |
| factor vii | #558 |
| vivo treatment | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| patients transfusion | #563 |
| board directors | #563 |
| risk development | #563 |
| female humans tests | #563 |
| anamnesis | #564 |
| appears | #564 |
| hip replacement | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| solid tumours | #566 |
| withholding | #566 |
| cardiac troponins | #566 |
| roc curves | #568 |
| patients 2 years | #568 |
| n46 | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| cutoff point | #574 |
| revascularization procedures | #574 |
| menstrual bleeding | #574 |
| women proportion | #575 |
| subcutaneously | #575 |
| major bleedings | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| endotoxin | #579 |
| pharma | #579 |
| thiophenes | #579 |
| notice | #580 |
| diagnostic tools | #580 |
| 99 | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| healthy human | #590 |
| reversal agents | #590 |
| thrombophilias | #590 |
| malignancy | #590 |
| beta alanine | #590 |
| massive pulmonary | #592 |
| conventional management | #592 |
| doppler ultrasound | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| ldf | #597 |
| patency rates | #597 |
| severe bleeding | #597 |
| replacement knee | #597 |
| major hemorrhage | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| comorbid conditions | #604 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| diagnostic studies | #606 |
| activated coagulation | #607 |
| 0·3 | #607 |
| patients antibodies | #607 |
| initial increase | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| tissue factor | #609 |
| arbitrage | #609 |
| patients death | #610 |
| 100 years | #610 |
| benefit risk | #610 |
| airline | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| reluctant | #615 |
| patients bariatric surgery | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| 467 | #618 |
| occurred | #618 |
| stroke atrial fibrillation | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| sgs | #623 |
| thrombocytopenia hit | #623 |
| thyrotoxic | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| warfarin risk | #628 |
| 66 | #628 |
| women risk factors | #628 |
| 5000 | #628 |
| referral patients | #629 |
| human subjects | #629 |
| physical training | #629 |
| diagnostic algorithms | #629 |
| absolute | #630 |
| sanofi | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| study quality | #641 |
| proceedings | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| studies efficacy | #648 |
| statin treatment | #648 |
| necessitating | #648 |
| 036 | #651 |
| thrombolysis patients | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| hemorrhagic stroke | #653 |
| fxa | #653 |
| 127 | #655 |
| patients review | #657 |
| bleeding death | #659 |
| 69 | #659 |
| coronary stent implantation | #659 |
| haematoma | #660 |
| physical examination | #661 |
| tertiles | #661 |
| coagulation proteins | #661 |
| haemophilia | #662 |
| clinical presentations | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| presence patients | #667 |
| guideline adherence | #667 |
| patients completed | #667 |
| onethird | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| elevated plasma | #673 |
| patients cteph | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| patients bleeding | #692 |
| ambulatory patients | #692 |
| graduated | #693 |
| activator pa | #693 |
| myocardial infarctions | #693 |
| precise mechanisms | #694 |
| composite outcome | #694 |
| intracranial bleeding | #694 |
| administer | #694 |
| 1718 | #695 |
| combined oral contraceptives | #696 |
| stroke prevention patients | #696 |
| moyamoya | #696 |
| difference 95 | #698 |
| ratio male | #698 |
| participant data | #698 |
| episode | #700 |
| compression devices | #700 |
| diagnostic errors | #702 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| surgery risk | #703 |
| patients confirmed | #703 |
| veins venous | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| medical patients | #712 |
| gynaecology | #712 |
| 048 | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| cancer groups | #717 |
| adequately | #717 |
| falsely | #718 |
| 10 30 | #718 |
| solid cancer | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| nordisk | #721 |
| pyrazoles pyridines | #721 |
| clinical judgment | #721 |
| accp | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| hull | #735 |
| disease pad | #735 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| clinical prediction rule | #736 |
| 6 12 | #739 |
| post hoc analysis | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| early pregnancy loss | #742 |
| 040 | #742 |
| unclear | #742 |
| topic predictive | #743 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| illness time factors | #744 |
| patients 50 years | #746 |
| etp | #746 |
| 285 | #746 |
| antithrombin activity | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| answer | #756 |
| pneumatic compression | #756 |
| 95 combination | #756 |
| 95 risk factors | #756 |
| hf risk | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| 435 | #763 |
| proportion women | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| 689 | #767 |
| aspirin clopidogrel | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| 566 | #770 |
| relevant | #770 |
| groups patients | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose intravenous | #778 |
| patients 65 years | #778 |
| study groups | #778 |
| dose warfarin | #778 |
| miscarriage | #779 |
| plasmin generation | #780 |
| 066 | #780 |
| thromboembolism prophylaxis | #780 |
| patients hyperthyroidism | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| cteph | #787 |
| general practitioners | #787 |
| 100 personyears | #787 |
| polypharmacy | #787 |
| topic disease models | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| mechanical heart | #793 |
| recombinant tissue | #793 |
| inactivators | #795 |
| 047 | #795 |
| risk factors risk | #795 |
| patency | #796 |
| patient years | #796 |
| eligible | #797 |
| studies prevalence | #797 |
| netherlands | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| estrogen therapy | #799 |
| theme | #799 |
| patients lower | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| adverse outcomes patients | #806 |
| fibrillation blood | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| factor vwf | #816 |
| flights | #816 |
| 0·4 | #818 |
| irrespective | #820 |
| vehicle control | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| antithrombotic treatment | #833 |
| 93 | #833 |
| myers | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| versus placebo | #837 |
| noac | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| antithrombotic therapy | #846 |
| 49 | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| patients diagnosis | #850 |
| caesarean | #850 |
| area roc curve | #852 |
| pre‐eclampsia | #853 |
| reference method | #853 |
| 30 patients | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| individual participant | #872 |
| longterm clinical outcomes | #872 |
| favoring | #873 |
| tasman | #873 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| targeted inhibition | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| male mexico | #894 |
| 084 | #894 |
| domiciliary | #894 |
| p011 | #896 |
| loading dose | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| patients clinical trials | #911 |
| documented | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| antagonist oral | #920 |
| randomeffects model | #920 |
| standard patients | #920 |
| loss patients | #921 |
| optimal dose | #921 |
| ultrasound examination | #921 |
| estimate male | #923 |
| practise | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| 902 | #928 |
| safer | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| stroke atrial | #944 |
| women preeclampsia | #944 |
| echocardiographically | #944 |
| emboli | #945 |
| predictive values | #946 |
| ssc | #946 |
| anticoagulation treatment | #947 |
| extensive disease | #948 |
| knee replacement | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| network metaanalysis | #956 |
| registro | #956 |
| cancer humans | #956 |
| dic | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| efficacy | #958 |
| day1 | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| risk allcause mortality | #973 |
| hoc | #973 |
| antiplatelet | #973 |
| prevalence characteristics | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| vascular humans | #976 |
| female fibrinogen | #976 |
| fvii | #978 |
| false negative | #979 |
| 50 100 | #980 |
| onset aged aged | #980 |
| 071 | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| missed | #991 |
| rises | #991 |
| academic medical center | #992 |
| seminar | #992 |
| normal lung | #993 |
| counteracted | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| justification | #1000 |
| lower extremity | #1000 |
| thromboembolic risk | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| extended | #1005 |
| interleukin 6 | #1005 |
| hyperprolactinaemia | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| easier | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| ticlopidine | #1018 |
| pounds | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| years risk | #1023 |
| cha2ds2 vasc | #1023 |
| international prospective | #1024 |
| humans randomized | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| risk hemorrhage | #1033 |
| relatives | #1033 |
| cardiovascular event | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| coagulant | #1060 |
| 179 | #1060 |
| birth rate | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| live birth | #1066 |
| 101 | #1066 |
| 00008 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| advocate | #1080 |
| 063 | #1080 |
| drawbacks | #1082 |
| longterm therapy | #1087 |
| f1 | #1087 |
| bandages | #1089 |
| clarifications | #1095 |
| stopping | #1095 |
| mandated | #1096 |
| idarucizumab | #1096 |
| diagnostic utility | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| blueprint | #1105 |
| fourfold | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| haemodialysis | #1116 |
| bypass grafts | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| probands | #1123 |
| resistance factor | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| heparininduced thrombocytopenia | #1127 |
| cip | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| superior efficacy | #1141 |
| 635 | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medical records | #1151 |
| medline | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| anticoagulation therapy | #1156 |
| blood loss | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| safety concerns | #1164 |
| hyperhomocysteinemia | #1164 |
| intermittent | #1164 |
| stable angina | #1164 |
| viii | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| crossover design | #1172 |
| glucocorticoid treatment | #1172 |
| perioperative bleeding | #1172 |
| atherosclerotic disease | #1172 |
| practice guideline | #1173 |
| occlusive diseases | #1173 |
| macroglobulin | #1176 |
| 5 years patients | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| hospitalized patients | #1182 |
| patients obesity | #1182 |
| unaware | #1182 |
| conclusive | #1186 |
| combined therapy | #1186 |
| degree relatives | #1189 |
| occult | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| international society | #1199 |
| mandate | #1199 |
| cardiotonic agents | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| 015 | #1204 |
| quantitative trait locus | #1204 |
| categorized | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| warranted | #1221 |
| patient treatment | #1221 |
| scores patients | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| peptide hydrolases | #1229 |
| trial background | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| doubles | #1232 |
| rules | #1232 |
| aspirin | #1234 |
| milliliter | #1238 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| subgroups | #1252 |
| matter lesions | #1252 |
| ml1 | #1252 |
| artery pulmonary | #1254 |
| search strategy | #1257 |
| extensive | #1257 |
| oral vitamin | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| troponins | #1266 |
| visiting | #1266 |
| entity | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| 75 years | #1281 |
| routine screening | #1281 |
| statin users | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| scan | #1295 |
| janssen | #1295 |
| perfusion defects | #1295 |
| predictive | #1297 |
| hemofiltration | #1297 |
| insufficiently | #1298 |
| cardiovascular complications | #1299 |
| low prevalence | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| pf4 | #1303 |
| 61 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| risk difference | #1312 |
| 1st | #1312 |
| cyproterone | #1312 |
| apoa | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| current strategies | #1314 |
| 0·7 | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| beneficial | #1329 |
| antibodies monoclonal antibodies | #1329 |
| vascular diseases | #1329 |
| plasminogen activators | #1330 |
| low moderate | #1330 |
| thyroid disorders | #1330 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 77 | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| surgical trauma | #1347 |
| antitrypsin | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| experimental model | #1359 |
| allcause mortality 95 | #1359 |
| 15 patients | #1359 |
| limb salvage | #1363 |
| vwf | #1363 |
| arsenal | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| 224 | #1385 |
| noninferiority | #1385 |
| dl1 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| record linkage | #1400 |
| patients control subjects | #1400 |
| equipoise | #1402 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| 1886 | #1405 |
| patients advanced cancer | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 6 weeks | #1419 |
| 3 6 | #1419 |
| 7 weeks | #1419 |
| thrombotic complications | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| 061 | #1424 |
| daily | #1424 |
| ≥55 | #1424 |
| eightfold | #1425 |
| randomised controlled trials | #1427 |
| 080 | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| imaging radiopharmaceuticals | #1439 |
| 096 | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| weight bmi | #1446 |
| outcome studies | #1446 |
| drug levels | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| 0·9 | #1468 |
| avoided | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| growing body | #1514 |
| adverse outcome | #1514 |
| proximal | #1516 |
| pregnancy postpartum | #1520 |
| ganz | #1520 |
| patients 10 | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| thrombotic events | #1527 |
| contraindicated | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| enfermedad | #1564 |
| pfa | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| cushings syndrome | #1568 |
| 95ci | #1568 |
| deficient | #1568 |
| hyperlipoproteinemia type | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| cocs | #1586 |
| activation markers | #1586 |
| study entry | #1586 |
| thyroid dysfunction | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| factors tomography | #1616 |
| positive effects | #1616 |
| prospective cohort studies | #1616 |
| tests reproducibility | #1616 |
| postpartum period | #1616 |
| 155 | #1618 |
| perinatal outcome | #1618 |
| female hemostasis | #1619 |
| cvd patients | #1619 |
| imaging tomography | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| pa patients | #1632 |
| incidentally | #1632 |
| venous disease | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| ≤4 | #1652 |
| 35 years | #1652 |
| studies data | #1653 |
| thrombin activity | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| daily dosing | #1676 |
| inpatient treatment | #1676 |
| deficiency | #1677 |
| plasma level | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| female femoral | #1721 |
| mb | #1721 |
| diagnostic evaluation | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| patients ventricular | #1745 |
| table | #1745 |
| 691 | #1745 |
| profession | #1746 |
| hyperinsulinaemia | #1747 |
| risk cardiovascular events | #1747 |
| turp | #1749 |
| apc | #1749 |
| homozygosity | #1750 |
| pselectin | #1750 |
| replacement | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| audiometry | #1760 |
| assessor | #1760 |
| treatment recommendations | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| arteriosclerosis | #1770 |
| hemorrhage | #1770 |
| allcause death | #1774 |
| 2 6 | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| 020 | #1802 |
| aggregation inhibitors | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| 1 week | #1842 |
| central venous | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| hydroxyethyl starch | #1852 |
| explanations | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 067 | #1897 |
| 5 10 | #1897 |
| contraindications | #1900 |
| extremity | #1901 |
| tnf | #1901 |
| diagnostic testing | #1901 |
| clt | #1905 |
| plaster | #1906 |
| hazard ratio | #1906 |
| induced thrombocytopenia | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| intracranial hemorrhage | #1927 |
| μg | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| safety effectiveness | #1950 |
| femoral vein | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| 48 hours | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| specificity ultrasonography | #1981 |
| 771 | #1981 |
| hyperaldosteronism | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| treatment cancer | #1986 |
| 1·0 | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| cvt | #1995 |
| computerized | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| clinical severity | #2000 |
| transient increase | #2000 |
| 3 months patients | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| varies | #2063 |
| requested | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| mcnemar | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| square distribution | #2092 |
| 114 | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| 59 | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 031 | #2109 |
| substantial | #2109 |
| 1966 | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| independently | #2118 |
| unnecessary | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| clinicaltrialsgov | #2122 |
| 11 | #2122 |
| coronary stent | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| controlled | #2129 |
| chose | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| congress | #2134 |
| protamines | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| committee | #2160 |
| oestrogens | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| advanced cancer | #2183 |
| 674 | #2183 |
| giant cell arteritis | #2185 |
| fifty | #2185 |
| 2 × | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| pravastatin | #2205 |
| increased patients | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| neutrophil elastase | #2212 |
| diagnosis differential | #2212 |
| doubled | #2213 |
| 364 | #2219 |
| pao2 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| 94 | #2225 |
| differential female | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| hivinfected patients | #2257 |
| clots | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| metaanalysis | #2267 |
| 6 months | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| nephelometry | #2316 |
| initial therapy | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| lacked | #2344 |
| inhibitor | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| predictable | #2377 |
| hemostasis | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| 757 | #2401 |
| patients liver cirrhosis | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| postinjection | #2413 |
| periodicals | #2413 |
| protein | #2413 |
| risk estimates | #2414 |
| sphingosine1 | #2415 |
| 22 | #2415 |
| internal medicine | #2424 |
| study drug | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| 0048 | #2430 |
| coagulants | #2430 |
| 002 | #2430 |
| legs | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| ptca | #2434 |
| prolonging | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 164 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hours | #2560 |
| haematology | #2560 |
| hydroxyethyl | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| humans logistic | #2574 |
| kits | #2574 |
| 73 | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| parenteral | #2606 |
| metaregression | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| trials rcts | #2635 |
| chondroitin | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| outcome ultrasonography | #2683 |
| 516 | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| aso | #2691 |
| 594 | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| 427 | #2739 |
| classifications | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| baseline characteristics | #2747 |
| patients asthma | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| antithyroid | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| 402 | #2802 |
| consecutive series | #2802 |
| reaching | #2805 |
| cirrhosis patients | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| helminth | #2836 |
| ketoprostaglandin | #2836 |
| kruskal | #2839 |
| crossover | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| post discharge | #2857 |
| new treatment | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| trimester pregnancy | #2880 |
| excessive | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| severe asthma | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 010 | #2960 |
| 270 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| declare | #2984 |
| lecture | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 50 years | #3040 |
| 419 | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| 80 | #3063 |
| nomogram | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| oac | #3122 |
| lifelong | #3122 |
| wallis | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 12 months | #3134 |
| 136 | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| 507 | #3153 |
| idiopathic | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| suggested | #3219 |
| cancer types | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| 198 | #3251 |
| bivalirudin | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| coumarin | #3289 |
| tumor markers | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| concluded | #3379 |
| humans lower | #3379 |
| 301 | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| tunica | #3403 |
| acute treatment | #3403 |
| 553 | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| preventive | #3419 |
| randomisation | #3419 |
| hypothesised | #3420 |
| surgical patients | #3420 |
| study risk | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| 168 | #3452 |
| prevalence incidence | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| 34 | #3470 |
| differ | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| inhibitors | #3506 |
| hemorrhagic complications | #3506 |
| treat | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| human cytomegalovirus | #3533 |
| lupus | #3533 |
| areas covered | #3537 |
| societies | #3541 |
| guidance | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| necessity | #3596 |
| prognosis prospective | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| treated | #3619 |
| platelet function | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| bypass surgery | #3642 |
| homozygote | #3642 |
| undergo | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| fibrillation | #3651 |
| interindividual variability | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| drug monitoring | #3721 |
| diagnostic process | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| humans intracranial | #3739 |
| effective | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| subgroup analyses | #3762 |
| 8 patients | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| clinicians patients | #3774 |
| computed ultrasonography | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| total knee arthroplasty | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| irs | #3856 |
| meeting | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 184 | #3890 |
| 351 | #3890 |
| difference | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| data studies | #3975 |
| 2nd | #3975 |
| quality assurance | #3980 |
| 986 | #3982 |
| pregnancy | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| introduction | #4045 |
| 296 | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| pcc | #4077 |
| bariatric | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| natriuretic peptide | #4089 |
| oligosaccharides | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| indications | #4099 |
| cutoff | #4099 |
| activation | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| p0005 | #4230 |
| crosssectional analysis | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| potential risk factors | #4350 |
| managed | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| negative | #4407 |
| bowel diseases | #4407 |
| 71 | #4407 |
| general | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| vascular surgery | #4459 |
| 192 | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| calculating | #4571 |
| cerebrovascular disorders | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| ranging | #4698 |
| unchanged | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| nonvalvular atrial fibrillation | #4870 |
| gpiib | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| fmd | #4913 |
| chlamydophila | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| orthopedics | #4982 |
| albeit | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| 389 | #5006 |
| references | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| bay | #5124 |
| vivo studies | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| female | #5131 |
| 131 | #5131 |
| transfused | #5134 |
| contrast media | #5136 |
| balancing | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| 36 patients | #5301 |
| thrombus | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| acute ischemic stroke | #5341 |
| reagent | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| continuing | #5499 |
| discomfort | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| erythema | #5539 |
| limitation | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| 80 years | #5644 |
| reclassification | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| mpo | #5804 |
| incidence rates | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| 1000 | #5819 |
| aircraft | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| ffa | #6160 |
| generation | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| mortality morbidity | #6228 |
| terminated | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| practitioners | #6273 |
| colleagues | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| washout | #6524 |
| triiodothyronine | #6524 |
| 318 | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| highrisk patients | #6532 |
| cochrane | #6532 |
| increased incidence | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| bowel | #6538 |
| exogenous | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| premedication | #6803 |
| reached | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| disturbances | #6912 |
| adverse event | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| intensity | #6976 |
| 246 | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| pectoris | #7338 |
| ischemic stroke | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| standardised | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| comorbid | #7578 |
| 191 | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| medical conditions | #7705 |
| 18 | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| hormone replacement | #7828 |
| label | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| preventable | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| parenteral nutrition | #8204 |
| confidence | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| activated | #8264 |
| 125i | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| transient ischemic | #8463 |
| procedures operative | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| covariate | #8501 |
| evaluate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| practical | #8756 |
| cardiovascular | #8756 |
| endovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| signs symptoms | #8945 |
| proportional hazards | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| mps | #9080 |
| diagnose | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| 212 | #9839 |
| craniotomy | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| heterozygotes | #9871 |
| nonhuman primates | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| pancreatic | #9997 |
| casecontrol studies | #9997 |
| 12 hours | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| investigations | #10199 |
| cell activation | #10199 |
| cardiovascular risk factors | #10209 |
| medical therapy | #10213 |
| clinical data | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| worldwide | #10337 |
| 667 | #10337 |
| greatly | #10352 |
| aorta | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| 159 | #10605 |
| microvascular | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| ethical | #11062 |
| summarizes | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| causality | #12208 |
| lung | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| escalation | #13107 |
| cancer risk | #13107 |
| vomiting | #13112 |
| physical | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| risk death | #14033 |
| members | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| situations | #14084 |
| focus | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| discuss | #15997 |
| severely | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| acute phase | #17288 |
| largest | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| 2002 | #20050 |
| gestational | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| majority | #21894 |
| 139 | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| naive | #23767 |
| adverse | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Key People For Pulmonary Embolism
Top KOLs in the world
Select a search phrase pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Expert Impact
Concepts for whichHarry Roger Büllerhas direct influence:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOL impact
Concepts related to the work of other authors for whichfor which Harry Roger Büller has influence:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |